Integer Holdings - 10-Q quarterly report FY2019 Q3

false--12-31Q3201900011144830.00256000003000000.0010.001100000000100000000326244943284118300.03250.02250.01750.00750.091250700000000P91DP91D151327172556<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a brief description of recent Accounting Standard Updates ("ASU") issued by the Financial Accounting Standards Board ("FASB") which are not yet effective for the Company</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:28%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a brief description of recent Accounting Standard Updates ("ASU") issued by the Financial Accounting Standards Board ("FASB") which are not yet effective for the Company</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:28%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Standard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effective Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:80px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div></div>00011144832018-12-292019-09-2700011144832019-10-2500011144832019-09-2700011144832018-12-2800011144832019-06-292019-09-2700011144832017-12-302018-09-2800011144832018-06-302018-09-2800011144832017-12-2900011144832018-06-290001114483us-gaap:AdditionalPaidInCapitalMember2017-12-302018-09-280001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-06-302018-09-280001114483us-gaap:RetainedEarningsMember2017-12-290001114483us-gaap:RetainedEarningsMember2019-06-2800011144832018-09-280001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-09-280001114483us-gaap:TreasuryStockMember2019-06-280001114483us-gaap:AdditionalPaidInCapitalMember2019-06-292019-09-270001114483us-gaap:TreasuryStockMember2018-09-280001114483us-gaap:AdditionalPaidInCapitalMember2018-12-292019-09-270001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-280001114483us-gaap:AdditionalPaidInCapitalMember2018-06-302018-09-280001114483us-gaap:TreasuryStockMember2017-12-290001114483us-gaap:TreasuryStockMember2019-09-270001114483us-gaap:RetainedEarningsMember2018-06-290001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-302018-09-280001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-270001114483us-gaap:RetainedEarningsMember2019-09-2700011144832019-06-280001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-280001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-290001114483us-gaap:RetainedEarningsMember2018-09-280001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-292019-09-270001114483us-gaap:TreasuryStockMember2018-06-290001114483us-gaap:TreasuryStockMember2018-12-280001114483us-gaap:RetainedEarningsMember2018-12-280001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-06-290001114483us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-292019-09-270001114483us-gaap:DiscontinuedOperationsHeldforsaleMembergb:ASOBusinessMember2019-06-292019-09-270001114483us-gaap:DiscontinuedOperationsHeldforsaleMembergb:ASOBusinessMember2017-12-302018-09-280001114483us-gaap:DiscontinuedOperationsHeldforsaleMembergb:ASOBusinessMember2018-12-292019-09-270001114483us-gaap:DiscontinuedOperationsHeldforsaleMembergb:ASOBusinessMember2018-06-302018-09-2800011144832019-04-142019-04-140001114483srt:ScenarioForecastMember2019-09-282020-01-0300011144832018-03-312018-06-2900011144832018-07-022018-07-0200011144832017-12-302018-12-280001114483us-gaap:SubsequentEventMember2019-10-072019-10-070001114483gb:SellingGeneralAndAdministrativeExpenseMember2018-12-292019-09-270001114483us-gaap:CostOfSalesMember2019-06-292019-09-270001114483us-gaap:CostOfSalesMember2017-12-302018-09-280001114483us-gaap:CostOfSalesMember2018-06-302018-09-280001114483gb:SellingGeneralAndAdministrativeExpenseMember2019-06-292019-09-270001114483gb:SellingGeneralAndAdministrativeExpenseMember2018-06-302018-09-280001114483gb:SellingGeneralAndAdministrativeExpenseMember2017-12-302018-09-280001114483us-gaap:ResearchAndDevelopmentExpenseMember2018-12-292019-09-270001114483us-gaap:ResearchAndDevelopmentExpenseMember2017-12-302018-09-280001114483us-gaap:ResearchAndDevelopmentExpenseMember2019-06-292019-09-270001114483us-gaap:ResearchAndDevelopmentExpenseMember2018-06-302018-09-280001114483us-gaap:CostOfSalesMember2018-12-292019-09-270001114483gb:PurchasedTechnologyAndPatentsMember2018-12-280001114483gb:PurchasedTechnologyAndPatentsMember2019-09-270001114483us-gaap:CustomerListsMember2019-09-270001114483us-gaap:OtherIntangibleAssetsMember2018-12-280001114483us-gaap:TrademarksAndTradeNamesMember2019-09-270001114483us-gaap:TrademarksAndTradeNamesMember2018-12-280001114483us-gaap:CustomerListsMember2018-12-280001114483us-gaap:OtherIntangibleAssetsMember2019-09-270001114483gb:NonMedicalSegmentMember2018-12-292019-09-270001114483gb:NonMedicalSegmentMember2019-09-270001114483gb:MedicalSegmentMember2018-12-280001114483gb:MedicalSegmentMember2019-09-270001114483gb:NonMedicalSegmentMember2018-12-280001114483gb:MedicalSegmentMember2018-12-292019-09-270001114483us-gaap:SecuredDebtMembergb:TermLoanATLAFacilityMemberus-gaap:LoansPayableMember2019-09-270001114483us-gaap:SecuredDebtMembergb:NewRevolvingCreditFacility2015Memberus-gaap:RevolvingCreditFacilityMember2018-12-280001114483us-gaap:SecuredDebtMembergb:TermLoanATLAFacilityMemberus-gaap:LoansPayableMember2018-12-280001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMemberus-gaap:LoansPayableMember2019-09-270001114483us-gaap:SecuredDebtMembergb:NewRevolvingCreditFacility2015Memberus-gaap:RevolvingCreditFacilityMember2019-09-270001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMemberus-gaap:LoansPayableMember2018-12-280001114483srt:MaximumMemberus-gaap:SecuredDebtMembergb:TermLoanATLAFacilityMemberus-gaap:LoansPayableMemberus-gaap:PrimeRateMember2015-10-272015-10-270001114483srt:MinimumMemberus-gaap:SecuredDebtMembergb:NewRevolvingCreditFacility2015Memberus-gaap:RevolvingCreditFacilityMember2015-10-272015-10-270001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMemberus-gaap:LoansPayableMemberus-gaap:LondonInterbankOfferedRateLIBORMember2015-10-272015-10-270001114483us-gaap:SecuredDebtMembergb:TermLoanATLAFacilityMemberus-gaap:LoansPayableMember2015-10-272015-10-270001114483us-gaap:SecuredDebtMembergb:NewRevolvingCreditFacility2015Membergb:SwinglineLoansMember2015-10-270001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMemberus-gaap:LoansPayableMember2015-10-272015-10-270001114483us-gaap:SeniorNotesMember2018-07-100001114483srt:MinimumMemberus-gaap:SecuredDebtMembergb:TermLoanATLAFacilityMemberus-gaap:LoansPayableMemberus-gaap:LondonInterbankOfferedRateLIBORMember2015-10-272015-10-270001114483srt:MinimumMemberus-gaap:SecuredDebtMembergb:TermLoanATLAFacilityMemberus-gaap:LoansPayableMemberus-gaap:PrimeRateMember2015-10-272015-10-270001114483us-gaap:SecuredDebtMembergb:TermLoanATLAFacilityMemberus-gaap:LoansPayableMember2015-10-270001114483us-gaap:SecuredDebtMembergb:NewRevolvingCreditFacility2015Memberus-gaap:RevolvingCreditFacilityMember2015-10-272015-10-270001114483us-gaap:SeniorNotesMember2015-10-270001114483us-gaap:SecuredDebtMembergb:NewRevolvingCreditFacility2015Memberus-gaap:RevolvingCreditFacilityMember2015-10-270001114483srt:MaximumMemberus-gaap:SecuredDebtMembergb:NewRevolvingCreditFacility2015Memberus-gaap:RevolvingCreditFacilityMember2015-10-272015-10-270001114483srt:MaximumMemberus-gaap:SecuredDebtMembergb:TermLoanATLAFacilityMemberus-gaap:LoansPayableMemberus-gaap:LondonInterbankOfferedRateLIBORMember2015-10-272015-10-270001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMemberus-gaap:LoansPayableMemberus-gaap:PrimeRateMember2015-10-272015-10-270001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMemberus-gaap:LoansPayableMember2015-10-270001114483us-gaap:SecuredDebtMembergb:NewRevolvingCreditFacility2015Memberus-gaap:StandbyLettersOfCreditMember2015-10-270001114483us-gaap:SeniorNotesMember2018-07-102018-07-100001114483us-gaap:SecuredDebtMembergb:TermLoanBTLBFacilityMemberus-gaap:LoansPayableMember2018-12-292019-09-270001114483srt:MaximumMemberus-gaap:SecuredDebtMembergb:NewRevolvingCreditFacility2015Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2015-10-272015-10-270001114483srt:MinimumMemberus-gaap:SecuredDebtMembergb:NewRevolvingCreditFacility2015Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2015-10-272015-10-270001114483srt:MaximumMemberus-gaap:SecuredDebtMembergb:NewRevolvingCreditFacility2015Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:PrimeRateMember2015-10-272015-10-270001114483srt:MinimumMemberus-gaap:SecuredDebtMembergb:NewRevolvingCreditFacility2015Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:PrimeRateMember2015-10-272015-10-270001114483gb:SeniorNotesDueNovember2023Memberus-gaap:SeniorNotesMember2019-09-270001114483us-gaap:InterestRateSwapMember2018-12-292019-09-270001114483us-gaap:EmployeeStockOptionMember2018-12-292019-09-270001114483us-gaap:EmployeeStockOptionMember2017-12-302018-09-280001114483gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember2019-09-270001114483gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember2018-12-292019-09-270001114483gb:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember2018-12-280001114483gb:RestrictedStockAndRestrictedStockUnitsTimeBasedMember2018-12-292019-09-270001114483gb:RestrictedStockAndRestrictedStockUnitsTimeBasedMember2019-09-270001114483gb:RestrictedStockAndRestrictedStockUnitsTimeBasedMember2018-12-280001114483us-gaap:SegmentContinuingOperationsMember2017-12-302018-09-280001114483gb:RestrictedStockAndUnitAwardsMember2019-06-292019-09-270001114483gb:IncomeStatementLocationDiscontinuedOperationsMember2019-06-292019-09-270001114483us-gaap:ResearchAndDevelopmentExpenseMember2018-12-292019-09-270001114483us-gaap:CostOfSalesMember2018-12-292019-09-270001114483us-gaap:SegmentContinuingOperationsMember2018-12-292019-09-270001114483us-gaap:CostOfSalesMember2019-06-292019-09-270001114483gb:IncomeStatementLocationDiscontinuedOperationsMember2017-12-302018-09-280001114483us-gaap:OtherOperatingIncomeExpenseMember2019-06-292019-09-270001114483gb:SellingGeneralAndAdministrativeExpenseMember2018-12-292019-09-270001114483gb:SellingGeneralAndAdministrativeExpenseMember2019-06-292019-09-270001114483gb:IncomeStatementLocationDiscontinuedOperationsMember2018-12-292019-09-270001114483us-gaap:SegmentContinuingOperationsMember2018-06-302018-09-280001114483gb:RestrictedStockAndUnitAwardsMember2018-06-302018-09-280001114483gb:RestrictedStockAndUnitAwardsMember2018-12-292019-09-270001114483us-gaap:OtherOperatingIncomeExpenseMember2018-12-292019-09-270001114483gb:SellingGeneralAndAdministrativeExpenseMember2017-12-302018-09-280001114483us-gaap:OtherOperatingIncomeExpenseMember2018-06-302018-09-280001114483gb:SellingGeneralAndAdministrativeExpenseMember2018-06-302018-09-280001114483gb:IncomeStatementLocationDiscontinuedOperationsMember2018-06-302018-09-280001114483us-gaap:OtherOperatingIncomeExpenseMember2017-12-302018-09-280001114483us-gaap:CostOfSalesMember2018-06-302018-09-280001114483us-gaap:CostOfSalesMember2017-12-302018-09-280001114483us-gaap:ResearchAndDevelopmentExpenseMember2018-06-302018-09-280001114483us-gaap:SegmentContinuingOperationsMember2019-06-292019-09-270001114483us-gaap:ResearchAndDevelopmentExpenseMember2019-06-292019-09-270001114483us-gaap:EmployeeStockOptionMember2018-06-302018-09-280001114483gb:RestrictedStockAndUnitAwardsMember2017-12-302018-09-280001114483us-gaap:ResearchAndDevelopmentExpenseMember2017-12-302018-09-280001114483us-gaap:EmployeeStockOptionMember2019-06-292019-09-270001114483gb:ManufacturingAlignmentToSupportGrowthMember2018-12-292019-09-270001114483gb:StrategicReorganizationAndAlignmentMember2018-06-302018-09-280001114483gb:ManufacturingAlignmentToSupportGrowthMember2018-06-302018-09-280001114483gb:AssetDispositionsSeveranceAndOtherMember2018-06-302018-09-280001114483gb:AssetDispositionsSeveranceAndOtherMember2018-12-292019-09-270001114483gb:ManufacturingAlignmentToSupportGrowthMember2017-12-302018-09-280001114483gb:ManufacturingAlignmentToSupportGrowthMember2019-06-292019-09-270001114483gb:ConsolidationAndOptimizationInitiativesMember2018-12-292019-09-270001114483gb:AssetDispositionsSeveranceAndOtherMember2019-06-292019-09-270001114483gb:ConsolidationAndOptimizationInitiativesMember2017-12-302018-09-280001114483gb:StrategicReorganizationAndAlignmentMember2018-12-292019-09-270001114483gb:ConsolidationAndOptimizationInitiativesMember2019-06-292019-09-270001114483gb:ConsolidationAndOptimizationInitiativesMember2018-06-302018-09-280001114483gb:StrategicReorganizationAndAlignmentMember2017-12-302018-09-280001114483gb:AssetDispositionsSeveranceAndOtherMember2017-12-302018-09-280001114483gb:StrategicReorganizationAndAlignmentMember2019-06-292019-09-270001114483gb:ConsolidationAndOptimizationInitiativesMembergb:SeveranceAndRetentionMember2018-12-292019-09-270001114483gb:ConsolidationAndOptimizationInitiativesMemberus-gaap:OtherRestructuringMember2019-09-270001114483gb:ConsolidationAndOptimizationInitiativesMembergb:SeveranceAndRetentionMember2018-12-280001114483gb:ConsolidationAndOptimizationInitiativesMember2019-09-270001114483gb:ConsolidationAndOptimizationInitiativesMemberus-gaap:OtherRestructuringMember2018-12-292019-09-270001114483gb:ConsolidationAndOptimizationInitiativesMemberus-gaap:OtherRestructuringMember2018-12-280001114483gb:ConsolidationAndOptimizationInitiativesMember2018-12-280001114483gb:ConsolidationAndOptimizationInitiativesMembergb:SeveranceAndRetentionMember2019-09-270001114483gb:StrategicReorganizationAndAlignmentMembersrt:MinimumMember2019-09-270001114483gb:StrategicReorganizationAndAlignmentMember2019-09-270001114483gb:ManufacturingAlignmentToSupportGrowthMembersrt:MaximumMember2019-09-270001114483gb:ManufacturingAlignmentToSupportGrowthMember2019-09-270001114483gb:ManufacturingAlignmentToSupportGrowthMembersrt:MinimumMember2019-09-270001114483gb:StrategicReorganizationAndAlignmentMembersrt:MaximumMember2019-09-2700011144832016-01-262016-01-260001114483us-gaap:PositiveOutcomeOfLitigationMember2016-01-262016-01-260001114483us-gaap:PositiveOutcomeOfLitigationMember2019-01-142019-01-140001114483us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-06-292019-09-270001114483us-gaap:SellingGeneralAndAdministrativeExpensesMember2018-12-292019-09-270001114483us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2018-06-302018-09-280001114483us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2017-12-302018-09-280001114483us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2017-12-302018-09-280001114483us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2017-12-302018-09-280001114483us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2018-06-302018-09-280001114483us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2018-06-302018-09-280001114483gb:ASOBusinessMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2018-06-302018-09-280001114483gb:ASOBusinessMemberus-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2018-06-302018-09-280001114483gb:ASOBusinessMember2018-06-302018-09-280001114483us-gaap:RestrictedStockMemberus-gaap:TreasuryStockCommonMember2017-12-302018-09-280001114483us-gaap:CommonStockMember2017-12-302018-09-280001114483us-gaap:CommonStockMember2019-09-270001114483us-gaap:CommonStockMember2018-09-280001114483us-gaap:TreasuryStockCommonMember2018-12-280001114483us-gaap:CommonStockMember2018-12-292019-09-270001114483us-gaap:RestrictedStockMemberus-gaap:CommonStockMember2017-12-302018-09-280001114483us-gaap:TreasuryStockCommonMember2018-12-292019-09-270001114483us-gaap:TreasuryStockCommonMember2017-12-290001114483us-gaap:CommonStockMember2018-12-280001114483us-gaap:TreasuryStockCommonMember2018-09-280001114483us-gaap:RestrictedStockMember2017-12-302018-09-280001114483us-gaap:CommonStockMember2017-12-290001114483us-gaap:TreasuryStockCommonMember2017-12-302018-09-280001114483us-gaap:TreasuryStockCommonMember2019-09-270001114483us-gaap:RestrictedStockMemberus-gaap:TreasuryStockCommonMember2018-12-292019-09-270001114483us-gaap:RestrictedStockMemberus-gaap:CommonStockMember2018-12-292019-09-270001114483us-gaap:RestrictedStockMember2018-12-292019-09-2700011144832019-03-302019-06-280001114483gb:ChineseVentureCapitalFundMember2019-09-270001114483us-gaap:RevenueFromContractWithCustomerMember2019-06-292019-09-270001114483us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2018-06-302018-09-280001114483us-gaap:CostOfGoodsTotalMember2017-12-302018-09-280001114483us-gaap:ForeignExchangeForwardMemberus-gaap:RevenueFromContractWithCustomerMember2018-06-302018-09-280001114483us-gaap:InterestExpenseMember2019-06-292019-09-270001114483us-gaap:RevenueFromContractWithCustomerMember2018-06-302018-09-280001114483us-gaap:InterestExpenseMember2017-12-302018-09-280001114483us-gaap:ForeignExchangeForwardMemberus-gaap:RevenueFromContractWithCustomerMember2018-12-292019-09-270001114483us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2019-06-292019-09-270001114483us-gaap:ForeignExchangeForwardMemberus-gaap:CostOfGoodsTotalMember2018-12-292019-09-270001114483us-gaap:ForeignExchangeForwardMemberus-gaap:RevenueFromContractWithCustomerMember2017-12-302018-09-280001114483us-gaap:CostOfGoodsTotalMember2018-12-292019-09-270001114483us-gaap:ForeignExchangeForwardMemberus-gaap:CostOfGoodsTotalMember2018-06-302018-09-280001114483us-gaap:CostOfGoodsTotalMember2018-06-302018-09-280001114483us-gaap:InterestExpenseMember2018-12-292019-09-270001114483us-gaap:CostOfGoodsTotalMember2019-06-292019-09-270001114483us-gaap:ForeignExchangeForwardMemberus-gaap:CostOfGoodsTotalMember2017-12-302018-09-280001114483us-gaap:InterestExpenseMember2018-06-302018-09-280001114483us-gaap:RevenueFromContractWithCustomerMember2017-12-302018-09-280001114483us-gaap:RevenueFromContractWithCustomerMember2018-12-292019-09-270001114483us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2018-12-292019-09-270001114483us-gaap:ForeignExchangeForwardMemberus-gaap:RevenueFromContractWithCustomerMember2019-06-292019-09-270001114483us-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2017-12-302018-09-280001114483us-gaap:ForeignExchangeForwardMemberus-gaap:CostOfGoodsTotalMember2019-06-292019-09-270001114483us-gaap:AccruedLiabilitiesMembergb:ForeignExchangeContractMaturingJune2019ContractOneMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-12-280001114483us-gaap:AccruedLiabilitiesMembergb:ForeignExchangeContractMaturingJune2019ContractThreeMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-12-280001114483us-gaap:AccruedLiabilitiesMembergb:ForeignExchangeContractMaturingJune2019ContractTwoMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-12-280001114483us-gaap:AccruedLiabilitiesMembergb:ForeignExchangeContractMaturingDecember2019Memberus-gaap:DesignatedAsHedgingInstrumentMember2018-12-280001114483us-gaap:AccruedLiabilitiesMembergb:ForeignExchangeContractMaturingJune2019ContractFourMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-12-280001114483gb:AccruedExpensesAndOtherCurrentLiabilitiesMembergb:ForeignExchangeContractMaturingJune2020ContractOneMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-09-270001114483gb:AccruedExpensesAndOtherCurrentLiabilitiesMembergb:ForeignExchangeContractMaturingDecember2019ContractTwoMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-09-270001114483gb:AccruedExpensesAndOtherCurrentLiabilitiesMembergb:ForeignExchangeContractMaturingDecember2019ContractOneMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-09-270001114483gb:AccruedExpensesAndOtherCurrentLiabilitiesMembergb:ForeignExchangeContractMaturingDecember2019ContractThreeMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-09-270001114483us-gaap:OtherNoncurrentLiabilitiesMembergb:InterestRateSwapMaturingJune2023Memberus-gaap:DesignatedAsHedgingInstrumentMember2019-09-270001114483gb:AccruedExpensesAndOtherCurrentLiabilitiesMembergb:InterestRateSwapMaturingJuly2020Memberus-gaap:DesignatedAsHedgingInstrumentMember2019-09-270001114483gb:AccruedExpensesAndOtherCurrentLiabilitiesMembergb:InterestRateSwapMaturingJune2020Memberus-gaap:DesignatedAsHedgingInstrumentMember2019-09-270001114483gb:AccruedExpensesAndOtherCurrentLiabilitiesMembergb:InterestRateSwapMaturingApril2020Memberus-gaap:DesignatedAsHedgingInstrumentMember2019-09-270001114483us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-09-270001114483us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-280001114483us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-280001114483us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-09-270001114483us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-280001114483us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-09-270001114483us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-280001114483us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-09-270001114483us-gaap:OperatingSegmentsMembergb:NonMedicalSegmentMember2018-12-292019-09-270001114483us-gaap:OperatingSegmentsMembergb:NonMedicalSegmentMember2018-06-302018-09-280001114483us-gaap:OperatingSegmentsMembergb:MedicalSegmentMember2018-12-292019-09-270001114483us-gaap:OperatingSegmentsMember2019-06-292019-09-270001114483us-gaap:OperatingSegmentsMembergb:NonMedicalSegmentMember2019-06-292019-09-270001114483us-gaap:OperatingSegmentsMember2017-12-302018-09-280001114483us-gaap:OperatingSegmentsMember2018-12-292019-09-270001114483us-gaap:MaterialReconcilingItemsMember2017-12-302018-09-280001114483us-gaap:OperatingSegmentsMembergb:MedicalSegmentMember2018-06-302018-09-280001114483us-gaap:MaterialReconcilingItemsMember2018-12-292019-09-270001114483us-gaap:MaterialReconcilingItemsMember2018-06-302018-09-280001114483us-gaap:OperatingSegmentsMembergb:MedicalSegmentMember2017-12-302018-09-280001114483us-gaap:OperatingSegmentsMembergb:MedicalSegmentMember2019-06-292019-09-270001114483us-gaap:OperatingSegmentsMember2018-06-302018-09-280001114483us-gaap:MaterialReconcilingItemsMember2019-06-292019-09-270001114483us-gaap:OperatingSegmentsMembergb:NonMedicalSegmentMember2017-12-302018-09-280001114483us-gaap:OperatingSegmentsMembergb:CardiacNeuromodulationMembergb:MedicalSegmentMember2018-06-302018-09-280001114483us-gaap:OperatingSegmentsMembergb:AdvancedSurgicalOrthopedicsandPortableMedicalMembergb:MedicalSegmentMember2019-06-292019-09-270001114483us-gaap:OperatingSegmentsMembergb:CardiacNeuromodulationMembergb:MedicalSegmentMember2017-12-302018-09-280001114483us-gaap:OperatingSegmentsMembergb:CardioAndVascularMembergb:MedicalSegmentMember2018-06-302018-09-280001114483us-gaap:OperatingSegmentsMembergb:AdvancedSurgicalOrthopedicsandPortableMedicalMembergb:MedicalSegmentMember2018-12-292019-09-270001114483us-gaap:OperatingSegmentsMembergb:CardiacNeuromodulationMembergb:MedicalSegmentMember2018-12-292019-09-270001114483us-gaap:OperatingSegmentsMembergb:CardioAndVascularMembergb:MedicalSegmentMember2019-06-292019-09-270001114483us-gaap:OperatingSegmentsMembergb:CardiacNeuromodulationMembergb:MedicalSegmentMember2019-06-292019-09-270001114483us-gaap:OperatingSegmentsMembergb:AdvancedSurgicalOrthopedicsandPortableMedicalMembergb:MedicalSegmentMember2017-12-302018-09-280001114483us-gaap:OperatingSegmentsMembergb:AdvancedSurgicalOrthopedicsandPortableMedicalMembergb:MedicalSegmentMember2018-06-302018-09-280001114483us-gaap:OperatingSegmentsMembergb:CardioAndVascularMembergb:MedicalSegmentMember2017-12-302018-09-280001114483us-gaap:OperatingSegmentsMembergb:CardioAndVascularMembergb:MedicalSegmentMember2018-12-292019-09-270001114483gb:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:NonMedicalSegmentMember2018-12-292019-09-270001114483gb:CustomerAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2019-06-292019-09-270001114483gb:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2018-12-292019-09-270001114483gb:CustomerCMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2018-12-292019-09-270001114483gb:CustomerEMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:NonMedicalSegmentMember2019-06-292019-09-270001114483gb:CustomerDMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:NonMedicalSegmentMember2018-12-292019-09-270001114483gb:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:NonMedicalSegmentMember2019-06-292019-09-270001114483gb:CustomerDMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:NonMedicalSegmentMember2019-06-292019-09-270001114483gb:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2019-06-292019-09-270001114483gb:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2018-12-292019-09-270001114483gb:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2019-06-292019-09-270001114483gb:CustomerAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2018-12-292019-09-270001114483gb:CustomerCMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2019-06-292019-09-270001114483country:USus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:NonMedicalSegmentMember2018-06-302018-09-280001114483gb:AllOtherCountriesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:NonMedicalSegmentMember2017-12-302018-09-280001114483country:USus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2017-12-302018-09-280001114483country:USus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:NonMedicalSegmentMember2017-12-302018-09-280001114483country:USus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2018-06-302018-09-280001114483gb:AllOtherCountriesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2018-06-302018-09-280001114483country:CAus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:NonMedicalSegmentMember2017-12-302018-09-280001114483gb:AllOtherCountriesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:NonMedicalSegmentMember2018-06-302018-09-280001114483gb:AllOtherCountriesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2017-12-302018-09-280001114483country:PRus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2017-12-302018-09-280001114483country:CAus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:NonMedicalSegmentMember2018-06-302018-09-280001114483country:PRus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2018-06-302018-09-280001114483gb:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2018-06-302018-09-280001114483gb:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:NonMedicalSegmentMember2018-06-302018-09-280001114483gb:CustomerCMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2017-12-302018-09-280001114483gb:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2017-12-302018-09-280001114483gb:CustomerCMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2018-06-302018-09-280001114483gb:CustomerAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2018-06-302018-09-280001114483gb:CustomerDMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:NonMedicalSegmentMember2018-06-302018-09-280001114483gb:CustomerAMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2017-12-302018-09-280001114483gb:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2018-06-302018-09-280001114483gb:CustomerDMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:NonMedicalSegmentMember2017-12-302018-09-280001114483gb:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:NonMedicalSegmentMember2017-12-302018-09-280001114483gb:AllOtherCustomersMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembergb:MedicalSegmentMember2017-12-302018-09-280001114483country:USus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2018-12-292019-09-270001114483gb:AllOtherCountriesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:NonMedicalSegmentMember2019-06-292019-09-270001114483gb:AllOtherCountriesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:NonMedicalSegmentMember2018-12-292019-09-270001114483gb:AllOtherCountriesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2018-12-292019-09-270001114483gb:AllOtherCountriesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2019-06-292019-09-270001114483country:PRus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2018-12-292019-09-270001114483country:PRus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2019-06-292019-09-270001114483country:CAus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:NonMedicalSegmentMember2018-12-292019-09-270001114483country:USus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:MedicalSegmentMember2019-06-292019-09-270001114483country:USus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:NonMedicalSegmentMember2019-06-292019-09-270001114483country:CAus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:NonMedicalSegmentMember2019-06-292019-09-270001114483country:USus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembergb:NonMedicalSegmentMember2018-12-292019-09-27xbrli:pureiso4217:USDxbrli:sharesgb:patentiso4217:USDxbrli:sharesiso4217:USDiso4217:MXNiso4217:USDiso4217:EURgb:Segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________________________________________

FORM 10-Q

_____________________________________________________________



(Mark One)
☒	QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 27, 2019



☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission File Number 1-16137

_____________________________________________________________

INTEGER HOLDINGS CORPORATION

(Exact name of Registrant as specified in its charter)

_____________________________________________________________



Delaware		16-1531026
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)



5830 Granite Parkway,	Suite 1150	Plano,	Texas	75024
(Address of principal executive offices)				(Zip Code)

(214) 618-5243

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	ITGR	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by checkmark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer	☒	Accelerated filer	☐	Non-accelerated filer	☐

Smaller reporting company	☐	Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares outstanding of the Company’s common stock, $0.001 par value per share, as of October 25, 2019 was: 32,678,605 shares.

INTEGER HOLDINGS CORPORATION

Form 10-Q

For the Quarterly Period Ended September 27, 2019

TABLE OF CONTENTS



		Page
PART I—FINANCIAL INFORMATION

ITEM 1.	Financial Statements	3

	Condensed Consolidated Balance Sheets (Unaudited)	3

	Condensed Consolidated Statements of Operations (Unaudited)	4

	Condensed Consolidated Statements of Comprehensive Income (Unaudited)	5

	Condensed Consolidated Statements of Cash Flows (Unaudited)	6

	Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)	7

	Notes to Condensed Consolidated Financial Statements (Unaudited)	8

ITEM 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	31

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	48

ITEM 4.	Controls and Procedures	48

PART II—OTHER INFORMATION

ITEM 1.	Legal Proceedings	49

ITEM 1A.	Risk Factors	49

ITEM 6.	Exhibits	49

SIGNATURES		50

- 2 -

PART I—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

INTEGER HOLDINGS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)



(in thousands except share and per share data)	September 27, 2019			December 28, 2018
ASSETS
Current assets:
Cash and cash equivalents	$	14,719		$	25,569
Accounts receivable, net of allowance for doubtful accounts of $0.3 million and $0.6 million, respectively	216,671			185,501
Inventories	197,977			190,076
Prepaid expenses and other current assets	23,704			15,104
Total current assets	453,071			416,250
Property, plant and equipment, net	230,683			231,269
Goodwill	825,318			832,338
Other intangible assets, net	774,744			812,338
Deferred income taxes	4,070			3,937
Operating lease assets	43,670			—
Other long-term assets	27,263			30,549
Total assets	$	2,358,819		$	2,326,681
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt	$	37,500		$	37,500
Accounts payable	77,383			57,187
Income taxes payable	12,228			9,393
Accrued expenses and other current liabilities	61,827			60,490
Total current liabilities	188,938			164,570
Long-term debt	790,420			888,007
Deferred income taxes	199,966			203,910
Operating lease liabilities	38,724			—
Other long-term liabilities	12,193			9,701
Total liabilities	1,230,241			1,266,188
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized; 32,841,183 and 32,624,494 shares issued, respectively; 32,668,627 and 32,473,167 shares outstanding, respectively	33			33
Additional paid-in capital	699,915			691,083
Treasury stock, at cost, 172,556 and 151,327 shares, respectively	(10,373		)	(8,125		)
Retained earnings	429,234			344,498
Accumulated other comprehensive income	9,769			33,004
Total stockholders’ equity	1,128,578			1,060,493
Total liabilities and stockholders’ equity	$	2,358,819		$	2,326,681

The accompanying notes are an integral part of these condensed consolidated financial statements.

- 3 -

INTEGER HOLDINGS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)



	Three Months Ended						Nine Months Ended
(in thousands except per share data)	September 27, 2019			September 28, 2018			September 27, 2019			September 28, 2018
Sales	$	303,587		$	305,088		$	932,457		$	911,978
Cost of sales	210,201			213,165			653,477			637,758
Gross profit	93,386			91,923			278,980			274,220
Operating expenses:
Selling, general and administrative expenses	32,935			34,091			101,034			107,300
Research, development and engineering costs	11,729			12,234			34,720			38,445
Other operating expenses	2,241			4,139			8,239			12,615
Total operating expenses	46,905			50,464			143,993			158,360
Operating income	46,481			41,459			134,987			115,860
Interest expense	12,337			54,526			39,779			85,355
(Gain) loss on equity investments, net	(986		)	(291		)	666			(5,545		)
Other (income) loss, net	(369		)	1,684			(921		)	257
Income (loss) from continuing operations before taxes	35,499			(14,460		)	95,463			35,793
Provision for (benefit from) income taxes	4,913			(6,157		)	15,289			7,956
Income (loss) from continuing operations	$	30,586		$	(8,303	)	$	80,174		$	27,837

Discontinued operations:
Income from discontinued operations before taxes	—			195,874			5,316			188,251
Provision for income taxes	—			73,492			178			73,869
Income from discontinued operations	$	—		$	122,382		$	5,138		$	114,382

Net income	$	30,586		$	114,079		$	85,312		$	142,219

Basic earnings (loss) per share:
Income (loss) from continuing operations	$	0.94		$	(0.26	)	$	2.46		$	0.87
Income from discontinued operations	—			3.80			0.16			3.57
Basic earnings per share	0.94			3.54			2.62			4.44

Diluted earnings (loss) per share:
Income (loss) from continuing operations	$	0.92		$	(0.26	)	$	2.43		$	0.86
Income from discontinued operations	—			3.80			0.16			3.52
Diluted earnings per share	0.92			3.54			2.58			4.38

Weighted average shares outstanding:
Basic	32,660			32,211			32,606			32,050
Diluted	33,068			32,211			33,019			32,451

The accompanying notes are an integral part of these condensed consolidated financial statements.

- 4 -

INTEGER HOLDINGS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)



	Three Months Ended						Nine Months Ended
(in thousands)	September 27, 2019			September 28, 2018			September 27, 2019			September 28, 2018
Comprehensive Income
Net income	$	30,586		$	114,079		$	85,312		$	142,219
Other comprehensive income:
Foreign currency translation loss	(14,810		)	(2,809		)	(17,138		)	(15,253		)
Change in fair value of cash flow hedges, net of tax	(1,352		)	634			(6,097		)	1,957
Other comprehensive loss, net of tax	(16,162		)	(2,175		)	(23,235		)	(13,296		)
Comprehensive income, net of tax	$	14,424		$	111,904		$	62,077		$	128,923

The accompanying notes are an integral part of these condensed consolidated financial statements.

- 5 -

INTEGER HOLDINGS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)



	Nine Months Ended
(in thousands)	September 27, 2019			September 28, 2018
Cash flows from operating activities:
Net income	$	85,312		$	142,219
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	57,397			68,447
Debt related charges included in interest expense	5,280			47,173
Stock-based compensation	6,894			7,684
Non-cash (gain) loss on equity investments	666			(1,043		)
Other non-cash gains	(1,088		)	(771		)
Deferred income taxes	(1,086		)	66,953
Gain on sale of discontinued operations	(4,974		)	(194,734		)
Changes in operating assets and liabilities:
Accounts receivable	(29,962		)	(4,805		)
Inventories	(8,567		)	(19,688		)
Prepaid expenses and other assets	(10,829		)	5,155
Accounts payable	17,760			10,488
Accrued expenses and other liabilities	(8,988		)	(14,904		)
Income taxes payable	4,162			8,562
Net cash provided by operating activities	111,977			120,736
Cash flows from investing activities:
Acquisition of property, plant and equipment	(24,704		)	(33,340		)
Proceeds from sale of property, plant and equipment	5			1,366
Purchase of equity investments	(417		)	(1,230		)
Proceeds from sale of discontinued operations	4,734			582,359
Net cash (used in) provided by investing activities	(20,382		)	549,155
Cash flows from financing activities:
Principal payments of long-term debt	(97,125		)	(670,094		)
Proceeds from senior secured revolving line of credit	20,000			—
Payments of senior secured revolving line of credit	(25,000		)	—
Proceeds from the exercise of stock options	2,654			11,757
Payment of debt issuance and redemption costs	—			(31,991		)
Tax withholdings related to net share settlements of restricted stock unit awards	(2,961		)	(2,568		)
Net cash used in financing activities	(102,432		)	(692,896		)
Effect of foreign currency exchange rates on cash and cash equivalents	(13		)	1,790
Net decrease in cash and cash equivalents	(10,850		)	(21,215		)
Cash and cash equivalents, beginning of period	25,569			44,096
Cash and cash equivalents, end of period	$	14,719		$	22,881

The accompanying notes are an integral part of these condensed consolidated financial statements.

- 6 -

INTEGER HOLDINGS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited)



	Three Months Ended						Nine Months Ended
(in thousands)	September 27, 2019			September 28, 2018			September 27, 2019			September 28, 2018
Total equity, beginning balance	$	1,111,695		$	917,734		$	1,060,493		$	893,381

Common stock and additional paid-in capital
Balance, beginning of period	697,681			678,188			691,116			669,788
Stock awards exercised or vested	806			7,912			1,938			10,205
Stock-based compensation	1,461			1,577			6,894			7,684
Balance, end of period	699,948			687,677			699,948			687,677
Treasury stock
Balance, beginning of period	(10,565		)	(5,720		)	(8,125		)	(4,654		)
Treasury shares purchased	(56		)	(359		)	(2,961		)	(2,568		)
Treasury shares reissued	248			411			713			1,554
Balance, end of period	(10,373		)	(5,668		)	(10,373		)	(5,668		)
Retained earnings
Balance, beginning of period	398,648			204,208			344,498			176,068
Adoption of ASC 842 (Note 1)	—			—			(576		)	—
Net income	30,586			114,079			85,312			142,219
Balance, end of period	429,234			318,287			429,234			318,287
Accumulated other comprehensive income
Balance, beginning of period	25,931			41,058			33,004			52,179
Other comprehensive loss	(16,162		)	(2,175		)	(23,235		)	(13,296		)
Reclassified to earnings, net	—			152			—			152
Balance, end of period	9,769			39,035			9,769			39,035
Total equity, ending balance	$	1,128,578		$	1,039,331		$	1,128,578		$	1,039,331

The accompanying notes are an integral part of these condensed consolidated financial statements.

- 7 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(1.) BASIS OF PRESENTATION

Integer Holdings Corporation (together with its consolidated subsidiaries, “Integer” or the “Company”) is a publicly-traded corporation listed on the New York Stock Exchange under the symbol “ITGR.” Integer is one of the largest medical device outsource manufacturers in the world serving the cardiac, neuromodulation, vascular, orthopedics, advanced surgical and portable medical markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in the energy, military, and environmental markets. The Company’s reportable segments are: (1) Medical and (2) Non-Medical. The Company’s customers include large multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries.

On May 3, 2018, the Company entered into a definitive agreement to sell the Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) within its Medical segment to Viant (formerly MedPlast, LLC), and on July 2, 2018 completed the sale. The results of operations of the AS&O Product Line are reported as discontinued operations in the Condensed Consolidated Statements of Operations for all periods presented. The Condensed Consolidated Statements of Cash Flows includes cash flows related to the discontinued operations due to Integer’s centralized treasury and cash management processes, and, accordingly, cash flow amounts for discontinued operations are disclosed in Note 2 “Discontinued Operations, Divestitures and Acquisitions.” All results and information in the condensed consolidated financial statements are presented as continuing operations and exclude the AS&O Product Line unless otherwise noted specifically as discontinued operations. Refer to Note 2 “Discontinued Operations, Divestitures and Acquisitions” for additional information.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. Intercompany transactions and balances have been fully eliminated in consolidation.

Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, certain components of equity, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 28, 2018.

Historically, the Company has utilized a 52/53-week fiscal year ending on the Friday nearest December 31. On October 9, 2019, the Board of Directors of Integer approved a change to the Company’s fiscal year from a year ending on the Friday nearest December 31 to a calendar year ending on December 31. Upon receipt of the customary approval of the lenders under the Company’s senior secured credit facilities, the Company’s current fiscal year will end on December 31, 2019, instead of January 3, 2020, with subsequent fiscal years beginning on January 1 and ending on December 31 of each year. The Company’s first three fiscal quarters in each fiscal year will continue to end on the Friday nearest March 31, June 30 and September 30, respectively. Fiscal year 2018 ended on December 28, 2018 and was a fifty-two week period.

The third quarter of 2019 and 2018 each contained 13 weeks and ended on September 27 and September 28, respectively, and were not impacted by the change in fiscal year.

Recent Accounting Pronouncements

The Company considers the applicability and impact of all Accounting Standard Updates (“ASU”) issued by the Financial Accounting Standards Board ("FASB"). ASUs not yet adopted that are not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated result of operations, financial position and cash flows. With the exception of the accounting pronouncements adopted as discussed below, there have been no new or material changes to the significant accounting policies discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2018, that are of significance, or potential significance, to the Company.

- 8 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(1.) BASIS OF PRESENTATION (Continued)

Recently Adopted Accounting Guidance

Adoption of ASC Topic 842

Effective December 29, 2018, the Company adopted ASC 842, Leases, which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. The Company elected to transition to ASC 842 using the option to not restate comparative periods and apply the standard as of the date of initial application. In addition, certain practical expedients were elected which permit the Company to not reassess whether existing contracts are or contain leases, to not reassess the lease classification of any existing leases, and to not reassess initial direct costs for any existing leases. The Company also elected the practical expedient to not separate lease and non-lease components for all classes of underlying assets and the practical expedient related to land easements, allowing the Company to carry-forward its accounting treatment for land easements on existing agreements. The Company did not elect the practical expedient pertaining to the use of hindsight. The Company also made an accounting policy election to keep leases with an initial term of 12 months or less and no purchase option the Company is reasonably certain to exercise off the balance sheet for all classes of underlying assets.

As a result of the adoption of ASC 842, the Company recognized operating lease right-of-use assets of $40.9 million and lease liabilities of $43.4 million on December 29, 2018. The difference between the lease assets and lease liabilities primarily represents the existing prepaid rent assets, deferred rent liabilities, and tenant improvement allowances, along with a cumulative-effect adjustment to beginning retained earnings. The adoption of ASC 842 did not have a material impact on the Company’s Condensed Consolidated Statement of Operations and Condensed Consolidated Statement of Cash Flows for the periods presented.

Refer to Note 11 “Leases” for additional information on the Company’s leases.

Adoption of ASU 2017-12 and ASU 2018-16

In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. ASU 2017-12 amends the designation and measurement guidance for qualifying hedging transactions and the presentation of hedge results in an entity’s financial statements. The new guidance removes the concept of separately measuring and reporting hedge ineffectiveness and requires a company to present the earnings effect of the hedging instrument, including any ineffectiveness, in the same income statement line item in which the earnings effect of the hedged item is reported.

ASU 2017-12 continues to allow an entity to exclude the time value of options and forward points from the assessment of hedge effectiveness. For excluded components in cash flow hedges, the base recognition model under this ASU is an amortization approach. An entity still may elect to record changes in the fair value of the excluded component currently in earnings; however, such an election will need to be applied consistently to similar hedges. The Company has elected to continue to record changes in the fair value of the excluded components of its derivative instruments currently in earnings given their highly effective nature.

Finally, this ASU continues to require an initial prospective quantitative hedge effectiveness assessment and documentation at hedge inception. However, if certain criteria are met, entities can elect to subsequently perform prospective and retrospective effectiveness assessments qualitatively, unless facts and circumstances change, and the hedge effectiveness assessment generally does not need to be completed until the first quarterly hedge effectiveness assessment date (i.e., up to three months).

The Company adopted ASU 2017-12 on December 29, 2018, the first day of the Company’s 2019 fiscal year, which did not materially affect the Company’s results of operations. The Company adopted the guidance on the modified retrospective basis and did not recognize a cumulative effect adjustment upon adoption as the Company had not recognized ineffectiveness on any of the hedging instruments existing as of the date of adoption. Refer to Note 14 “Financial Instruments and Fair Value Measurements” for additional information and disclosures of the Company’s derivatives and hedging activities.

In October 2018, the FASB issued ASU 2018-16, Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. The amendments in ASU 2018-16 permit the use of the OIS rate based on SOFR as a benchmark interest rate for hedge accounting purposes under Topic 815. The amendments in this update were effective for fiscal years beginning after December 15, 2018. The Company adopted this guidance prospectively as of December 29, 2018, concurrent with the adoption of ASU 2017-12, to be applied on a prospective basis for qualifying new or redesignated hedging relationships entered into on or after the date of adoption. Adoption of this guidance had no impact on the Condensed Consolidated Financial Statements.

- 9 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(1.) BASIS OF PRESENTATION (Continued)

Not Yet Adopted Accounting Guidance

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the current incurred loss impairment methodology for most financial assets with the current expected credit loss (“CECL”) methodology. Under the CECL method, the Company will be required to immediately recognize an estimate of credit losses expected to occur over the life of the financial asset at the time financial asset is originated or acquired. Estimated credit losses are determined by taking into consideration historical loss conditions, current conditions and reasonable and supportable forecasts. Changes to the expected lifetime credit losses are required to be recognized each period. The standard will be effective for the Company on January 1, 2020 and will be adopted using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings in the period of adoption. The Company has initiated implementation efforts and is in the process of accumulating historical, current and forward-looking information to be used in the estimation of credit losses. The Company is assessing the risk characteristics related to trade receivables and contract assets, which are the primary financial assets of the Company that will be within the scope of this guidance. The adoption of ASU 2016-13 is not expected to have a material impact to on the Condensed Consolidated Financial Statements.

(2.) DISCONTINUED OPERATIONS, DIVESTITURES AND ACQUISITIONS

AS&O Divestiture

On May 3, 2018, the Company entered into a definitive agreement to sell its AS&O Product Line to Viant, and on July 2, 2018, completed the sale, collecting cash proceeds of approximately $581 million, which is net of transaction costs and adjustments set forth in the definitive agreement. In connection with the sale, the parties executed a transition services agreement whereby the Company would provide certain corporate services (including accounting, payroll, and information technology services) to Viant for a period of up to one year from the date of the closing to facilitate an orderly transfer of business operations. Viant paid Integer for these services as specified in the transition services agreement, which were complete as of June 28, 2019. Accordingly, there was no income recognized under the transition services agreement during the three months ended September 27, 2019. The Company recognized $2.9 million of income under the transition services agreement for the performance of services during the nine months ended September 27, 2019, of which $0.1 million is recorded as a reduction of Cost of sales and $2.8 million is recorded as a reduction of Selling, general and administrative expenses. The Company recognized $1.9 million of income under the transition services agreement for the performance of services during the three and nine months ended September 28, 2018, of which $0.1 million is recorded as a reduction of Cost of sales and $1.8 million is recorded as a reduction of Selling, general and administrative expenses. In addition, the parties executed long-term supply agreements under which the Company and Viant have agreed to supply the other with certain products at prices specified in the agreements for a term of three years.

In connection with the closing of the transaction but prior to a net working capital adjustment, the Company recognized a pre-tax gain on sale of discontinued operations of $195.0 million during the year ended December 28, 2018. During the nine months ended September 27, 2019, the Company received $4.8 million due to a net working capital adjustment agreed to with Viant. This was recognized as gain on sale from discontinued operations during the quarter ended June 28, 2019.

- 10 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(2.) DISCONTINUED OPERATIONS, DIVESTITURES AND ACQUISITIONS (Continued)

The operating results of the AS&O Product Line have been classified as discontinued operations in the Condensed Consolidated Statements of Operations for all periods presented. The discontinued operations of the AS&O Product Line are reported in the Medical segment. Income from discontinued operations net of taxes, were as follows (in thousands):



	Three Months Ended					Nine Months Ended
	September 27, 2019		September 28, 2018			September 27, 2019			September 28, 2018
Sales	$	—	$	—		$	—		$	178,020
Cost of sales	—		—			—			148,357
Gross profit	—		—			—			29,663
Selling, general and administrative expenses	—		—			—			8,905
Research, development and engineering costs	—		—			—			2,352
Other operating expenses (income)⁽¹⁾	—		(2,185		)	—			1,805
Interest expense	—		976			—			22,833
Gain on sale of discontinued operations	—		(194,734		)	(4,974		)	(194,734		)
Other (income) loss, net	—		69			(342		)	251
Income from discontinued operations before taxes	—		195,874			5,316			188,251
Provision for income taxes	—		73,492			178			73,869
Income from discontinued operations	$	—	$	122,382		$	5,138		$	114,382

^__________


⁽¹⁾	The Company recorded $2.2 million of transaction costs in Other operating expenses (income) from discontinued operations during the three months ended June 29, 2018, which were reclassified to the Gain on sale of discontinued operations during the three months ended September 28, 2018.

Cash flow information from discontinued operations was as follows (in thousands):



	Nine Months Ended
	September 27, 2019			September 28, 2018
Cash used in operating activities	$	(58	)	$	(12,388	)
Cash provided by (used in) investing activities	4,734			578,763
Depreciation and amortization	—			7,450
Capital expenditures	—			3,610

Acquisition of Assets from US BioDesign, LLC

On October 7, 2019, the Company acquired certain assets of US BioDesign, LLC, a privately held developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The acquisition adds a differentiated capability related to the complex development and manufacture of braided and formed biomedical structures to the Company’s broad portfolio. The Company paid $15 million in cash and may pay up to an additional $5.5 million of contingent earn out over the next four years based on specified conditions being met. The Company expects to determine the preliminary purchase price allocation prior to the end of the fourth quarter of 2019.

- 11 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)


(3.)	SUPPLEMENTAL CASH FLOW INFORMATION

The following is supplemental information relating to the Condensed Consolidated Statements of Cash Flows, including information related to discontinued operations:



	Nine Months Ended
(in thousands)	September 27, 2019		September 28, 2018
Noncash investing and financing activities:
Property, plant and equipment purchases included in accounts payable	$	5,125	$	2,585

Refer to Note 2 “Discontinued Operations, Divestitures and Acquisitions” for additional supplemental cash flow information pertaining to discontinued operations and Note 11 “Leases” for additional supplemental cash flow information pertaining to leases.

(4.) INVENTORIES

Inventories are comprised of the following (in thousands):



	September 27, 2019		December 28, 2018
Raw materials	$	83,171	$	80,213
Work-in-process	78,803		75,711
Finished goods	36,003		34,152
Total	$	197,977	$	190,076

- 12 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(5.) GOODWILL AND OTHER INTANGIBLE ASSETS, NET

Goodwill

The changes in the carrying amount of goodwill by reportable segment for the nine months ended September 27, 2019 were as follows (in thousands):



	Medical			Non- Medical		Total
December 28, 2018	$	815,338		$	17,000	$	832,338
Foreign currency translation	(7,020		)	—		(7,020		)
September 27, 2019	$	808,318		$	17,000	$	825,318

Intangible Assets

Intangible assets at September 27, 2019 and December 28, 2018 were as follows (in thousands):



	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
September 27, 2019
Definite-lived:
Purchased technology and patents	$	239,905	$	(134,560	)	$	105,345
Customer lists	702,723		(123,617		)	579,106
Other	3,503		(3,498		)	5
Total	$	946,131	$	(261,675	)	$	684,456
Indefinite-lived:
Trademarks and tradenames						$	90,288

December 28, 2018
Definite-lived:
Purchased technology and patents	$	241,726	$	(125,540	)	$	116,186
Customer lists	710,406		(104,556		)	605,850
Other	3,503		(3,489		)	14
Total	$	955,635	$	(233,585	)	$	722,050
Indefinite-lived:
Trademarks and tradenames						$	90,288

Aggregate intangible asset amortization expense is comprised of the following (in thousands):



	Three Months Ended				Nine Months Ended
	September 27, 2019		September 28, 2018		September 27, 2019		September 28, 2018
Cost of sales	$	3,165	$	3,367	$	9,622	$	10,756
Selling, general and administrative expenses	6,617		6,490		19,845		20,196
Research, development and engineering costs	—		39		—		116
Total intangible asset amortization expense	$	9,782	$	9,896	$	29,467	$	31,068

Estimated future intangible asset amortization expense based on the carrying value as of September 27, 2019 is as follows (in thousands):



	Remainder of 2019		2020	2021	2022	2023	After 2023
Amortization Expense	$	10,492	40,065	39,219	38,194	36,359	520,127

- 13 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(6.) DEBT

Long-term debt is comprised of the following (in thousands):



	September 27, 2019			December 28, 2018
Senior secured term loan A	$	276,563		$	304,687
Senior secured term loan B	563,286			632,286
Revolving line of credit	—			5,000
Unamortized discount on term loan B and debt issuance costs	(11,929		)	(16,466		)
Total debt	827,920			925,507
Current portion of long-term debt	(37,500		)	(37,500		)
Total long-term debt	$	790,420		$	888,007

The Company has senior secured credit facilities (the “Senior Secured Credit Facilities”) as of September 27, 2019, consisting of (i) a revolving credit facility (the “Revolving Credit Facility”) with $200 million of borrowing capacity as described below, (ii) a $277 million term loan A facility (the “TLA Facility”), and (iii) a $563 million term loan B facility (the “TLB Facility”). The TLA Facility and TLB Facility are collectively referred to as the “Term Loan Facilities.” The TLB Facility was issued at a 1% discount.

Revolving Credit Facility

The Revolving Credit Facility matures on October 27, 2020. The Revolving Credit Facility includes a $15 million sublimit for swingline loans and a $25 million sublimit for standby letters of credit. The Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which will range between 0.175% and 0.25%, depending on the Company’s Total Net Leverage Ratio (as defined in the Senior Secured Credit Facilities agreement). As of September 27, 2019, the commitment fee on the unused portion of the Revolving Credit Facility was 0.25%. Interest rates on the Revolving Credit Facility, as well as the TLA Facility, are at the Company’s option, either at: (i) the prime rate plus the applicable margin, which will range between 0.75% and 2.25%, based on the Company’s Total Net Leverage Ratio, or (ii) the applicable LIBOR rate plus the applicable margin, which will range between 1.75% and 3.25%, based on the Company’s Total Net Leverage Ratio.

As of September 27, 2019, the Company had no outstanding borrowings on the Revolving Credit Facility and an available borrowing capacity of $193.2 million after giving effect to $6.8 million of outstanding standby letters of credit.

Term Loan Facilities

The TLA Facility and TLB Facility mature on October 27, 2021 and October 27, 2022, respectively. Interest rates on the TLB Facility are, at the Company’s option, either at: (i) the prime rate plus 2.00% or (ii) the applicable LIBOR rate plus 3.00%, with LIBOR subject to a 1.00% floor. As of September 27, 2019, the interest rates on the TLA Facility and TLB Facility were 4.31% and 5.05%, respectively.

Covenants

The Revolving Credit Facility and TLA Facility contain covenants requiring (A) a maximum Total Net Leverage Ratio of 4.75:1.00, subject to quarterly step downs of 25 basis points beginning in the fourth quarter of 2019 and ending in the second quarter of 2020 and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of not less than 3.00:1.00. The TLB Facility does not contain any financial maintenance covenants. As of September 27, 2019, the Company was in compliance with these financial covenants.

9.125% Senior Notes due 2023

On October 27, 2015, the Company completed a private offering of $360 million aggregate principal amount of 9.125% senior notes due on November 1, 2023 (the “Senior Notes”). On July 10, 2018, the Company completed the redemption in full of the Senior Notes at a redemption price of 100% of the principal amount of the Senior Notes plus the applicable “make-whole” premium of $31.3 million and accrued and unpaid interest through the redemption date. The “make-whole” premium is included in Interest Expense for the three and nine months ended September 28, 2018 in the accompanying Condensed Consolidated Statements of Operations.

- 14 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(6.) DEBT (Continued)

Contractual maturities under the Senior Secured Credit Facilities for the remainder of 2019 and the next three years (through maturity), excluding any discounts or premiums, as of September 27, 2019 are as follows (in thousands):



	2019		2020	2021	2022
Future minimum principal payments	$	9,375	37,500	229,688	563,286

The Company prepaid portions of its TLB Facility during 2019 and 2018. The Company recognized losses from extinguishment of debt during the three and nine months ended September 27, 2019 of $0.3 million and $1.3 million, respectively. The Company recognized losses from extinguishment of debt during the three and nine months ended September 28, 2018 of $9.3 million and $10.8 million, respectively. The loss from extinguishment of debt represents the portion of the unamortized discount and debt issuance costs related to the portion of the TLB Facility that was prepaid and is included in Interest Expense in the accompanying Condensed Consolidated Statements of Operations. The loss from extinguishment of debt for the three and nine months ended September 28, 2018 also includes the unamortized debt issuance costs related to the Senior Notes.

(7.) STOCK-BASED COMPENSATION

The Company maintains certain stock-based compensation plans that were approved by the Company’s stockholders and are administered by the Board of Directors, or the Compensation and Organization Committee of the Board. The stock-based compensation plans provide for the granting of stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers.

The components and classification of stock-based compensation expense were as follows (in thousands):



	Three Months Ended					Nine Months Ended
	September 27, 2019		September 28, 2018			September 27, 2019		September 28, 2018
Stock options	$	101	$	215		$	304	$	726
RSAs and RSUs	1,360		1,872			6,590		6,544
Stock-based compensation expense - continuing operations	1,461		2,087			6,894		7,270
Discontinued operations	—		(510		)	—		414
Total stock-based compensation expense	$	1,461	$	1,577		$	6,894	$	7,684

Cost of sales	$	168	$	222		$	766	$	598
Selling, general and administrative expenses	1,155		1,821			5,819		6,568
Research, development and engineering costs	69		44			193		99
Other operating expenses	69		—			116		5
Discontinued operations	—		(510		)	—		414
Total stock-based compensation expense	$	1,461	$	1,577		$	6,894	$	7,684

There were no stock options granted during the nine months ended September 27, 2019. The weighted average fair value and assumptions used to value options granted during the nine months ended September 28, 2018 are as follows:



Weighted average fair value	$	14.89
Risk-free interest rate	2.21		%
Expected volatility	39		%
Expected life (in years)	4.0
Expected dividend yield	—		%

- 15 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(7.) STOCK-BASED COMPENSATION (Continued)

The following table summarizes the Company’s stock option activity:



	Number of Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (In Years)	Aggregate Intrinsic Value (In Millions)
Outstanding at December 28, 2018	522,783		$	31.88
Exercised	(116,904	)	22.70
Outstanding at September 27, 2019	405,879		$	34.52	5.3	$	16.3
Exercisable at September 27, 2019	371,564		$	34.10	5.1	$	15.1

During the nine months ended September 27, 2019, the Company awarded grants to members of its Board of Directors and certain members of management. The Board of Directors received grants of time-based RSUs that vest in equal quarterly installments of 25% on the first day of each quarter of the Company’s 2019 fiscal year. The members of management received either time-based RSUs or a mix of time-based RSUs and performance-based RSUs (“PRSUs”). The time-based RSUs vest ratably, subject to the recipient’s continuous service to the Company over a period of generally three to four years from the grant date. For the Company's PRSUs, in addition to service conditions, the ultimate number of shares to be earned depends on the achievement of financial performance or market-based conditions. The financial performance condition is based on the Company's sales targets. The market-based conditions are based on the Company’s achievement of a relative total shareholder return (“TSR”) performance requirement, on a percentile basis, compared to a defined group of peer companies over three year performance periods.

The Company uses a Monte Carlo simulation model to determine the grant-date fair value of awards with TSR-based performance conditions. The grant-date fair value of all other RSAs and RSUs is equal to the closing market price of Integer common stock on the date of grant.

The weighted average fair value and assumptions used to value the TSR portion of the PRSUs granted are as follows:



	Nine Months Ended
	September 27, 2019			September 28, 2018
Weighted average fair value	$	117.03		$	37.46
Risk-free interest rate	2.46		%	2.28		%
Expected volatility	40		%	40		%
Expected life (in years)	2.8			2.9
Expected dividend yield	—		%	—		%

The following table summarizes RSA and RSU activity:



	Time-Vested Activity		Weighted Average Fair Value
Nonvested at December 28, 2018	142,236		$	49.78
Granted	104,636		82.96
Vested	(24,752	)	63.34
Forfeited	(16,009	)	57.49
Nonvested at September 27, 2019	206,111		$	64.40

- 16 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(7.) STOCK-BASED COMPENSATION (Continued)

The following table summarizes PRSU activity:



	Performance- Vested Activity		Weighted Average Fair Value
Nonvested at December 28, 2018	287,134		$	36.15
Granted	50,492		101.17
Vested	(75,008	)	28.41
Forfeited	(68,153	)	34.17
Nonvested at September 27, 2019	194,465		$	56.71

(8.) OTHER OPERATING EXPENSES

Other Operating Expenses is comprised of the following (in thousands):



	Three Months Ended					Nine Months Ended
	September 27, 2019		September 28, 2018			September 27, 2019		September 28, 2018
Strategic reorganization and alignment	$	962	$	2,643		$	4,352	$	8,424
Manufacturing alignment to support growth	515		877			1,661		2,493
Consolidation and optimization initiatives	—		137			—		698
Asset dispositions, severance and other	764		482			2,226		1,000
Other operating expenses - continuing operations	2,241		4,139			8,239		12,615
Discontinued operations⁽¹⁾	—		(2,185		)	—		1,805
Total other operating expenses	$	2,241	$	1,954		$	8,239	$	14,420

^__________


⁽¹⁾	The Company recorded $2.2 million of transaction costs in Other operating expenses (income) from discontinued operations during the three months ended June 29, 2018, which were reclassified to the Gain on sale of discontinued operations during the three months ended September 28, 2018.

Strategic Reorganization and Alignment

As a result of the strategic review of its customers, competitors and markets, the Company began taking steps in 2017 to better align its resources in order to enhance the profitability of its portfolio of products. These initiatives include improving its business processes and redirecting investments away from projects where the market does not justify the investment, as well as aligning resources with market conditions and the Company’s future strategic direction. The Company estimates that it will incur aggregate pre-tax charges in connection with the strategic reorganization and alignment plan, including projects reported in discontinued operations, of between approximately $20 million to $22 million, the majority of which are expected to be cash expenditures. During the nine months ended September 27, 2019, the Company incurred charges relating to this initiative, which primarily included severance and fees for professional services recorded within the Medical segment. As of September 27, 2019, total expense incurred for this initiative since inception, including amounts reported in discontinued operations, was $20.9 million. These actions are expected to be substantially completed by the end of 2019.

Manufacturing Alignment to Support Growth

In 2017, the Company initiated several initiatives designed to reduce costs, increase manufacturing capacity to accommodate growth and improve operating efficiencies. The plan involves the relocation of certain manufacturing operations and expansion of certain of the Company's facilities. The Company estimates that it will incur aggregate pre-tax restructuring related charges in connection with the realignment plan of between approximately $6 million to $7 million, the majority of which are expected to be cash expenditures. Costs related to the Company’s manufacturing alignment to support growth initiative were primarily recorded within the Medical segment. As of September 27, 2019, total expense incurred for this initiative since inception, including amounts reported in discontinued operations, was $5.1 million. These actions are expected to be substantially completed by the end of 2019.

- 17 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(8.) OTHER OPERATING EXPENSES (Continued)

Consolidation and Optimization Initiatives

Costs related to the Company’s consolidation and optimization initiatives were primarily recorded within the Medical segment. The Company does not expect to incur any material additional costs associated with these activities.

The following table summarizes the change in accrued liabilities, presented within Accrued Expense and Other Current Liabilities on the Condensed Consolidated Balance Sheets, related to the initiatives described above (in thousands):



	Severance and Retention			Other			Total
December 28, 2018	$	1,668		$	202		$	1,870
Restructuring charges	1,345			4,668			6,013
Cash payments	(1,629		)	(4,863		)	(6,492		)
September 27, 2019	$	1,384		$	7		$	1,391

Asset Dispositions, Severance and Other

During the nine months ended September 27, 2019 and September 28, 2018, the Company recorded expenses related to other initiatives not described above, which relate primarily to integration and operational initiatives to reduce future operating costs and improve operational efficiencies.

(9.) INCOME TAXES

The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including discrete items, changes in the mix and amount of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. In addition, the Company continues to explore tax planning opportunities that may have a material impact on its effective tax rate.

The Company’s effective tax rate for continuing operations for the third quarter of 2019 was 13.8% on $35.5 million of income from continuing operations before taxes compared to 42.6% on $14.5 million of losses from continuing operations before taxes for the same period in 2018. The Company’s effective tax rate for continuing operations for the nine months ended September 27, 2019 was 16.0% on $95.5 million of income from continuing operations before taxes compared to 22.2% on $35.8 million of income from continuing operations before taxes for the same period of 2018. The difference between the Company’s effective tax rates and the U.S. federal statutory income tax rate of 21% for the third quarter of 2019 and nine months ended September 27, 2019 is primarily attributable to discrete tax benefits of $2.3 million and $4.4 million, respectively, as well as the estimated net impact of the Global Intangible Low-Taxed Income tax, the Company’s earnings outside the U.S., which are generally taxed at rates that differ from the U.S federal rate, and the availability of certain tax credits. The discrete tax benefits for 2019 are predominately related to excess tax benefits recognized upon vesting of RSUs or exercise of stock options, favorable return to provision adjustments related to the 2018 tax year, and the release of certain reserves for unrecognized tax benefits.

As of September 27, 2019 and December 28, 2018, the Company had unrecognized tax benefits from continuing operations of approximately $4.2 million and $5.4 million, respectively. During the third quarter of 2019, the Company obtained information that impacted its judgment regarding the sustainability of certain tax deductions taken in prior years. As a result, the Company released $1.2 million of unrecognized tax benefits as a discrete item during the third quarter of 2019. It is reasonably possible that a reduction of up to $0.6 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of potential audit settlements. As of September 27, 2019 and December 28, 2018, approximately $4.1 million and $5.3 million, respectively, of the unrecognized tax benefits would favorably impact the effective tax rate, net of federal benefit on state issues, if recognized.

- 18 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(10.) COMMITMENTS AND CONTINGENCIES

Litigation

The Company is subject to litigation arising from time to time in the ordinary course of its business. The Company does not expect that the ultimate resolution of any pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, will not become material in the future.

In April 2013, the Company commenced an action against AVX Corporation and AVX Filters Corporation (collectively “AVX”) alleging that AVX had infringed on the Company’s patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate the Company’s patented technology. Two juries in the U.S. District Court for the District of Delaware have returned verdicts finding that AVX infringed on three of the Company’s patents and awarded the Company $37.5 million in damages. In March 2018, the U.S. District Court for the District of Delaware vacated the original damage award and ordered a retrial on damages. In the January 2019 retrial on damages, the jury awarded the Company $22.2 million in damages. On July 31, 2019, the U.S. District Court for the District of Delaware entered an order denying AVX’s post-trial motion to overturn the jury verdict in favor of the Company. On August 23, 2019, AVX filed its notice of appeal with the United States Court of Appeals for the Federal Circuit. On September 5, 2019, the Company filed its notice of cross-appeal with the United States Court of Appeals for the Federal Circuit. To date, the Company has recorded no gains in connection with this litigation.

Product Warranties

The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The Company does not expect future product warranty claims will have a material effect on its condensed consolidated results of operations, financial position, or cash flows. However, there can be no assurance that any future customer complaints or negative regulatory actions regarding the Company’s products, which the Company currently believes to be immaterial, does not become material in the future. The product warranty liability is presented within Accrued Expense and Other Current Liabilities on the Condensed Consolidated Balance Sheets. The change in product warranty liability was comprised of the following (in thousands):



December 28, 2018	$	2,600
Additions to warranty reserve	441
Adjustments to pre-existing warranties	(988		)
Warranty claims settled	(1,221		)
September 27, 2019	$	832

- 19 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(11.) LEASES

The Company primarily leases certain office and manufacturing facilities under operating leases, with additional operating leases for machinery, office equipment and vehicles. An arrangement is considered to contain a lease if it conveys the right to use an identified asset for a period of time in exchange for consideration. If it is determined that an arrangement contains a lease, classification of a lease as operating or finance is determined by evaluating the five criteria outlined within ASC 842 at inception. The Company does not currently have any finance leases. The Company’s lease agreements do not contain any residual value guarantees or any material restrictive covenants.

Right-of-use (“ROU”) lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make payments in exchange for that right of use. Operating lease ROU assets are presented as Operating Lease Assets, the current portion of operating lease liabilities are presented within Accrued Expense and Other Current Liabilities, and the non-current portion of operating lease liabilities are presented as Operating Lease Liabilities on the Condensed Consolidated Balance Sheets. The current portion of operating lease liabilities was $7.3 million as of September 27, 2019. Leases with a term of 12 months or less are not recorded on the balance sheet.

The Company’s real estate leases often contain options to renew, and less frequently, termination options. The exercise of such renewal and termination options are generally at the Company’s sole discretion. The Company evaluates renewal and termination options at lease commencement to determine if such options are reasonably certain to be exercised based on economic factors.

For certain leases where rent escalates based upon a change in a financial index, such as the Consumer Price Index, the difference between the rate at lease inception and the subsequent fluctuations in that rate are included in variable lease costs. Additionally, because the Company has elected to not separate lease and non-lease components, variable costs also include payments to the landlord for common area maintenance, real estate taxes, insurance and other operating expenses. Lease expense is recognized on a straight-line basis over the lease term, with variable lease payments recognized in the period those payments are incurred.

The discount rate implicit within the Company’s leases is not readily determinable, and therefore, the Company uses its estimated incremental borrowing rate in determining the present value of lease payments. The incremental borrowing rate is determined based on the Company’s recent debt issuances, lease term and the currency in which lease payments are made.

The following table presents the weighted average remaining lease term and discount rate:



	September 27, 2019
Weighted-average remaining lease term of operating leases (in years)	7.6
Weighted-average discount rate of operating leases	5.5	%

The components and classification of lease cost are as follows (in thousands):



	Three Months Ended September 27, 2019			Nine Months Ended September 27, 2019
Operating lease cost	$	2,470		$	7,361
Short-term lease cost (leases with initial term of 12 months or less)	12			46
Variable lease cost	638			1,845
Sublease income	(475		)	(1,420		)
Total lease cost	$	2,645		$	7,832

Cost of sales	$	2,220		$	6,562
Selling, general and administrative expenses	285			837
Research, development and engineering costs	138			416
Other operating expenses	2			17
Total lease cost	$	2,645		$	7,832

- 20 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(11.) LEASES (Continued)

The Company’s sublease income is derived primarily from certain real estate leases to several non-affiliated tenants under operating sublease arrangements.

At September 27, 2019, the maturities of operating lease liabilities were as follows (in thousands):



Remainder of 2019	$	2,519
2020	9,454
2021	9,132
2022	7,055
2023	6,274
2024	5,752
Thereafter	16,615
Total lease payments	56,801
Less imputed interest	(10,852		)
Total	$	45,949

As of September 27, 2019, the Company did not have any leases that have not yet commenced.

Supplemental cash flow information related to leases for the nine months ended September 27, 2019 is as follows (in thousands):



Cash paid for amounts included in the measurement of operating lease liabilities	$	7,713
ROU assets obtained in exchange for new operating lease liabilities	8,215

During the nine months ended September 27, 2019, the Company extended the lease terms for four of its manufacturing facilities. As a result of these lease modifications, the Company re-measured the lease liability and adjusted the ROU asset on the modification dates.

The Company’s future minimum lease commitments, net of sublease income, as of December 28, 2018, under ASC 840, the predecessor to ASC 842, are as follows (in thousands):



	2019		2020	2021	2022	2023	After 2023
Future minimum lease payments	$	8,562	7,290	7,348	5,269	5,112	14,589

- 21 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(12.) EARNINGS (LOSS) PER SHARE (“EPS”)

The following table sets forth a reconciliation of the information used in computing basic and diluted EPS (in thousands, except per share amounts):



	Three Months Ended					Nine Months Ended
	September 27, 2019		September 28, 2018			September 27, 2019		September 28, 2018
Numerator for basic and diluted EPS:
Income (loss) from continuing operations	$	30,586	$	(8,303	)	$	80,174	$	27,837
Income from discontinued operations	—		122,382			5,138		114,382
Net income	$	30,586	$	114,079		$	85,312	$	142,219

Denominator for basic and diluted EPS:
Weighted average shares outstanding - Basic	32,660		32,211			32,606		32,050
Dilutive effect of share-based awards	408		—			413		401
Weighted average shares outstanding - Diluted	33,068		32,211			33,019		32,451

Basic earnings (loss) per share:
Income (loss) from continuing operations	$	0.94	$	(0.26	)	$	2.46	$	0.87
Income from discontinued operations	—		3.80			0.16		3.57
Basic earnings per share	0.94		3.54			2.62		4.44

Diluted earnings (loss) per share:
Income (loss) from continuing operations	$	0.92	$	(0.26	)	$	2.43	$	0.86
Income from discontinued operations	—		3.80			0.16		3.52
Diluted earnings per share	0.92		3.54			2.58		4.38

The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands):



	Three Months Ended		Nine Months Ended
	September 27, 2019	September 28, 2018	September 27, 2019	September 28, 2018
Time-vested stock options, RSAs and RSUs	—	797	29	436
Performance-vested restricted stock and PRSUs	50	303	48	220

(13.) STOCKHOLDERS’ EQUITY

The following is a summary of the number of shares of common stock issued, treasury stock and common stock outstanding for the nine month periods ended September 27, 2019 and September 28, 2018:



	Nine Months Ended September 27, 2019				Nine Months Ended September 28, 2018
	Issued	Treasury Stock		Outstanding	Issued	Treasury Stock		Outstanding
Balance, beginning of period	32,624,494	(151,327	)	32,473,167	31,977,953	(106,526	)	31,871,427
Stock options exercised	116,904	—		116,904	381,793	—		381,793
RSAs issued, net of forfeitures, and vesting of RSUs	99,785	(21,229	)	78,556	141,963	(12,496	)	129,467
Balance, end of period	32,841,183	(172,556	)	32,668,627	32,501,709	(119,022	)	32,382,687

- 22 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(13.) STOCKHOLDERS’ EQUITY (Continued)

Accumulated Other Comprehensive Income (“AOCI”) is comprised of the following (in thousands):



	Defined Benefit Plan Liability			Cash Flow Hedges			Foreign Currency Translation Adjustment			Total Pre-Tax Amount			Tax			Net-of-Tax Amount
June 28, 2019	$	(295	)	$	(2,567	)	$	28,211		$	25,349		$	582		$	25,931
Unrealized loss on cash flow hedges	—			(1,459		)	—			(1,459		)	307			(1,152		)
Realized loss on foreign currency hedges	—			191			—			191			(40		)	151
Realized gain on interest rate swap hedge	—			(444		)	—			(444		)	93			(351		)
Foreign currency translation loss	—			—			(14,810		)	(14,810		)	—			(14,810		)
September 27, 2019	$	(295	)	$	(4,279	)	$	13,401		$	8,827		$	942		$	9,769

December 28, 2018	$	(295	)	$	3,439		$	30,539		$	33,683		$	(679	)	$	33,004
Unrealized loss on cash flow hedges	—			(6,028		)	—			(6,028		)	1,266			(4,762		)
Realized loss on foreign currency hedges	—			157			—			157			(33		)	124
Realized gain on interest rate swap hedges	—			(1,847		)	—			(1,847		)	388			(1,459		)
Foreign currency translation loss	—			—			(17,138		)	(17,138		)	—			(17,138		)
September 27, 2019	$	(295	)	$	(4,279	)	$	13,401		$	8,827		$	942		$	9,769



June 29, 2018	$	(1,422	)	$	5,094		$	37,756		$	41,428		$	(370	)	$	41,058
Unrealized gain on cash flow hedges	—			1,424			—			1,424			(299		)	1,125
Realized gain on foreign currency hedges	—			(141		)	—			(141		)	30			(111		)
Realized gain on interest rate swap hedges	—			(482		)	—			(482		)	102			(380		)
Foreign currency translation loss	—			—			(2,809		)	(2,809		)	—			(2,809		)
Reclassifications to earnings⁽¹⁾	948			—			(514		)	434			(282		)	152
September 28, 2018	$	(474	)	$	5,895		$	34,433		$	39,854		$	(819	)	$	39,035

December 29, 2017	$	(1,422	)	$	3,418		$	50,200		$	52,196		$	(17	)	$	52,179
Unrealized gain on cash flow hedges	—			4,325			—			4,325			(908		)	3,417
Realized gain on foreign currency hedges	—			(734		)	—			(734		)	154			(580		)
Realized gain on interest rate swap hedge	—			(1,114		)	—			(1,114		)	234			(880		)
Foreign currency translation loss	—			—			(15,253		)	(15,253		)	—			(15,253		)
Reclassifications to earnings⁽¹⁾	948			—			(514		)	434			(282		)	152
September 28, 2018	$	(474	)	$	5,895		$	34,433		$	39,854		$	(819	)	$	39,035

^__________

⁽¹⁾

Accumulated foreign currency translation losses of $0.5 million and defined benefit plan liabilities of $0.7 million (net of income taxes of $0.3 million) were reclassified to earnings during the three months ended September 28, 2018 as a result of the divestiture of the AS&O Product Line and are included in “Gain on sale of discontinued operations, net of tax” in the Condensed Consolidated Statements of Operations.

- 23 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(14.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

Assets and Liabilities Measured at Fair Value on a Recurring Basis

Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis.

The Company is exposed to global market risks, including the effect of changes in interest rates and foreign currency exchange rates, and uses derivatives to manage these exposures that occur in the normal course of business. The Company does not hold or issue derivatives for trading or speculative purposes. All derivatives are recorded at fair value on the balance sheet.

Interest Rate Swaps

The Company periodically enters into interest rate swap agreements in order to reduce the cash flow risk caused by interest rate changes on its outstanding floating rate borrowings. Under these swap agreements, the Company pays a fixed rate of interest and receives a floating rate equal to one-month London Interbank Offered Rate (“LIBOR”). The variable rate received from the swap agreements and the variable rate paid on the outstanding debt will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The Company has designated these swap agreements as cash flow hedges based on concluding the hedged forecasted transaction is probable of occurring within the period the cash flow hedge is anticipated to affect earnings. The unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and are subsequently reclassified into earnings when interest on the related debt is accrued.

The fair value of the Company’s swap agreements are determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. In addition, the Company receives a fair value estimate from the swap agreement counterparty to verify the reasonableness of the Company’s estimate. The estimated fair value of the swap agreements represents the amount the Company would receive (pay) to terminate the contracts.

Information regarding the Company’s outstanding interest rate swaps designated as cash flow hedges as of September 27, 2019 is as follows (dollars in thousands):



Notional Amount		Start Date	End Date	Pay Fixed Rate		Receive Current Floating Rate		Fair Value			Balance Sheet Location
$	200,000	Jun 2017	Jun 2020	1.1325	%	2.0536	%	$	883		Accrued expenses and other current liabilities
75,000		Jul 2019	Jul 2020	1.8900		2.0536		(90		)	Accrued expenses and other current liabilities
400,000		Apr 2019	Apr 2020	2.4150		2.0421		(1,306		)	Accrued expenses and other current liabilities
200,000		Jun 2020	Jun 2023	2.1785		^(a)		(3,753		)	Other long-term liabilities

^__________

^(a) The interest rate swap is not in effect until June 2020.

As of December 28, 2018, the Company had outstanding an interest rate swap with a notional amount of $200 million. The fair value as of December 28, 2018 was $4.2 million and was included in Other assets in the Condensed Consolidated Balance Sheets.

Foreign Currency Contracts

The Company periodically enters into foreign currency forward contracts to hedge its exposure to foreign currency exchange rate fluctuations in its international operations. The Company has designated these foreign currency forward contracts as cash flow hedges. The unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and are reclassified to earnings in the same periods during which the hedged transactions affect earnings.

- 24 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(14.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of September 27, 2019 is as follows (dollars in thousands):



Notional Amount		Start Date	End Date	$/Foreign Currency		Fair Value			Balance Sheet Location
$	5,249	Jul 2019	Dec 2019	0.0500	Peso	$	26		Accrued expenses and other current liabilities
6,042		Jul 2019	Dec 2019	0.0504	Peso	(12		)	Accrued expenses and other current liabilities
8,339		Oct 2019	Dec 2019	1.1119	Euro	(95		)	Accrued expenses and other current liabilities
11,166		Jan 2020	Jun 2020	0.0490	Peso	68			Accrued expenses and other current liabilities

Information regarding outstanding foreign currency contracts designated as cash flow hedges as of December 28, 2018 is as follows (dollars in thousands):



Notional Amount		Start Date	End Date	$/Foreign Currency		Fair Value			Balance Sheet Location
$	12,621	Jan 2019	Jun 2019	1.1686	Euro	$	(149	)	Accrued Expenses
10,991		Jan 2019	Jun 2019	0.0523	Peso	(494		)	Accrued Expenses
10,535		Jan 2019	Jun 2019	1.1705	Euro	(141		)	Accrued Expenses
11,019		Jan 2019	Jun 2019	0.0483	Peso	(316		)	Accrued Expenses
10,499		Jul 2019	Dec 2019	0.0500	Peso	368			Accrued Expenses

The fair value of foreign currency contracts are determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs include foreign exchange rates and credit spread curves. In addition, the Company receives fair value estimates from the foreign currency contract counterparties to verify the reasonableness of the Company’s estimates.

Derivative Instruments with Hedge Accounting Designation

The following tables present the fair values of derivative instruments formally designated as hedging instruments as of September 27, 2019 and December 28, 2018 (in thousands).



		Fair Value
	Fair Value Hierarchy	Assets		Liabilities
September 27, 2019
Interest rate swaps	Level 2	$	—	$	4,266
Foreign currency contracts	Level 2	—		13

December 28, 2018
Interest rate swaps	Level 2	$	4,171	$	—
Foreign currency contracts	Level 2	—		732

- 25 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(14.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

The following tables present the amounts in the Condensed Consolidated Statements of Operations in which the effects of cash flow hedges are recorded and the effects of cash flow hedge activity on these line items for the three and nine months ended September 27, 2019 and September 28, 2018 (in thousands):



	Three Months Ended
	September 27, 2019					September 28, 2018
	Total		Amount of Gain (Loss) on Cash Flow Hedge Activity			Total		Amount of Gain (Loss) on Cash Flow Hedge Activity
Sales	$	303,587	$	(500	)	$	305,088	$	(252	)
Cost of sales	210,201		309			213,165		393
Interest expense	12,337		444			54,526		482



	Nine Months Ended
	September 27, 2019					September 28, 2018
	Total		Amount of Gain (Loss) on Cash Flow Hedge Activity			Total		Amount of Gain (Loss) on Cash Flow Hedge Activity
Sales	$	932,457	$	(1,294	)	$	911,978	$	(254	)
Cost of sales	653,477		1,137			637,758		988
Interest expense	39,779		1,847			85,355		1,114

The following tables present the amounts affecting the Condensed Consolidated Statements of Operations for the three and nine months ended September 27, 2019 and September 28, 2018 (in thousands):



	Amount of Gain (Loss) Recognized in Other Comprehensive Income (Loss) on Derivatives						Amount of Gain (Loss) Reclassified from AOCI into Earnings
	Three months ended,						Location of Gain (Loss) Reclassified from AOCI into Earnings	Three months ended,
	September 27, 2019			September 28, 2018				September 27, 2019			September 28, 2018
Interest rate swap	$	(991	)	$	415		Interest expense	$	444		$	482
Foreign exchange forwards	(400		)	384			Sales	(500		)	(252		)
Foreign exchange forwards	(68		)	625			Cost of sales	309			393

	Nine Months Ended						Location of Gain (Loss) Reclassified from AOCI into Earnings	Nine Months Ended
	September 27, 2019			September 28, 2018				September 27, 2019			September 28, 2018
Interest rate swap	$	(6,590	)	$	2,524		Interest expense	$	1,847		$	1,114
Foreign exchange forwards	(1,099		)	(92		)	Sales	(1,294		)	(254		)
Foreign exchange forwards	1,661			1,893			Cost of sales	1,137			988

The Company expects to reclassify net losses totaling $0.5 million related to its cash flow hedges from AOCI into earnings during the next twelve months.

- 26 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(14.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these items.

Borrowings under the Company’s Revolving Credit Facility, TLA Facility and TLB Facility accrue interest at a floating rate tied to a standard short-term borrowing index, selected at the Company’s option, plus an applicable margin. The carrying amount of this floating rate debt approximates fair value based upon the respective interest rates adjusting with market rate adjustments.

Equity Investments

The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other Long-Term Assets on the Condensed Consolidated Balance Sheets. Non-marketable equity securities are equity securities without readily determinable fair value. The Company has elected the practicability exception to use an alternative approach that measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. If an impairment is recognized on the Company’s non-marketable equity securities during the period, these assets are classified as Level 3 within the fair value hierarchy based on the nature of the fair value inputs.

Equity investments are comprised of the following (in thousands):



	September 27, 2019		December 28, 2018
Equity method investment	$	15,977	$	15,148
Non-marketable equity securities	6,092		7,667
Total equity investments	$	22,069	$	22,815

The components of (Gain) Loss on Equity Investments, Net for each period were as follows (in thousands):



	Three Months Ended						Nine Months Ended
	September 27, 2019			September 28, 2018			September 27, 2019			September 28, 2018
Equity method investment income	$	(986	)	$	(291	)	$	(909	)	$	(5,545	)
Impairment charges	—			—			1,575			—
Observable price adjustments on non-marketable equity securities	—			—			—			—
Total (gain) loss on equity investments, net	$	(986	)	$	(291	)	$	666		$	(5,545	)

In May 2019, the Company determined that an investment in one of its non-marketable equity securities was impaired and determined the fair value to be zero based upon available market information. An impairment charge of $1.6 million was recognized during the second quarter of 2019. This assessment was based on qualitative indications of impairment. Factors that significantly influenced the determination of the impairment loss included the equity security’s investee’s financial condition, priority claims to the equity security, distributions rights and preferences, and status of the regulatory approval required to bring its product to market.

The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. As of September 27, 2019, the Company owned 6.7% of this fund.

- 27 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(15.) SEGMENT INFORMATION

The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker, to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, Segment Reporting. For purposes of segment reporting, intercompany sales between segments are not material.

The following table presents sales from continuing operations by product line (in thousands).



	Three Months Ended				Nine Months Ended
	September 27, 2019		September 28, 2018		September 27, 2019		September 28, 2018
Segment sales from continuing operations by product line:
Medical
Cardio & Vascular	$	148,581	$	150,230	$	451,552	$	435,859
Cardiac & Neuromodulation	106,533		109,620		337,932		334,471
Advanced Surgical, Orthopedics & Portable Medical	34,310		32,789		98,544		101,481
Total Medical	289,424		292,639		888,028		871,811
Non-Medical	14,163		12,449		44,429		40,167
Total sales from continuing operations	$	303,587	$	305,088	$	932,457	$	911,978

The following table presents income from continuing operations for the Company’s reportable segments (in thousands).



	Three Months Ended						Nine Months Ended
	September 27, 2019			September 28, 2018			September 27, 2019			September 28, 2018
Segment income from continuing operations:
Medical	$	62,648		$	58,929		$	182,734		$	167,623
Non-Medical	3,318			3,521			12,927			11,112
Total segment income	65,966			62,450			195,661			178,735
Unallocated operating expenses	(19,485		)	(20,991		)	(60,674		)	(62,875		)
Operating income	46,481			41,459			134,987			115,860
Unallocated expenses, net	(10,982		)	(55,919		)	(39,524		)	(80,067		)
Income (loss) from continuing operations before taxes	$	35,499		$	(14,460	)	$	95,463		$	35,793

- 28 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)


(16.)	REVENUE FROM CONTRACTS WITH CUSTOMERS

Revenue Recognition

The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their affiliated subsidiaries. Revenue is recognized when performance obligations are satisfied and the customer has obtained control of the products. Under the provisions of the majority of the Company’s contracts with customers, revenue is recognized at the point in time when title and risk of ownership transfers to the customer, which is primarily determined based upon the shipping terms. When contracts with customers for products that do not have an alternative use to the Company contain provisions that provide the Company with an enforceable right to payment for performance completed to date with a recapture of costs incurred plus an applicable margin throughout the duration of the contract, revenue is recognized over time as control is deemed to have transferred to the customer. The Company uses an input measure to determine progress towards completion and total estimated costs at completion. Under this method, sales and gross profit are recognized as work is performed generally based on actual costs incurred. For arrangements recognized over time, the Company records a contract asset for unbilled revenue associated with non-cancellable customer orders. Revenue is recognized net of sales tax, value-added taxes and other taxes.

Disaggregated Revenue

In general, the Company's business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment's results of operations. For a summary by disaggregated product line sales for each segment, refer to Note 15, “Segment Information.”

Revenue recognized from products and services transferred to customers over time represented 10% and 11%, respectively, of total revenue for the three and nine months ended September 27, 2019, substantially all of which was within the Medical segment. The Company did not have any significant revenue related to contracts recognized over time for the nine months ended September 28, 2018.

The following table presents revenues by significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues.



	Three Months Ended				Nine Months Ended
	September 27, 2019				September 27, 2019
Customer	Medical		Non-Medical		Medical		Non-Medical
Customer A	20	%	*		22	%	*
Customer B	18	%	*		18	%	*
Customer C	13	%	*		12	%	*
Customer D	*		22	%	*		24	%
Customer E	*		12	%	*		*
All other customers	49	%	66	%	48	%	76	%

(16.) REVENUE FROM CONTRACTS WITH CUSTOMERS (Continued)



	Three Months Ended				Nine Months Ended
	September 28, 2018				September 28, 2018
Customer	Medical		Non-Medical		Medical		Non-Medical
Customer A	23	%	*		22	%	*
Customer B	20	%	*		19	%	*
Customer C	12	%	*		12	%	*
Customer D	*		30	%	*		28	%
All other customers	45	%	70	%	47	%	72	%

^__________

* Less than 10% of segment’s total revenues for the period.

- 29 -

INTEGER HOLDINGS CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

The following table presents revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped.



	Three Months Ended		Nine Months Ended
	September 27, 2019		September 27, 2019
Ship to Location	Medical	Non-Medical	Medical	Non-Medical
United States	55%	61%	56%	58%
Puerto Rico	11%	*	13%	*
Canada	*	12%	*	13%
All other countries	34%	27%	31%	29%



	Three Months Ended		Nine Months Ended
	September 28, 2018		September 28, 2018
Ship to Location	Medical	Non-Medical	Medical	Non-Medical
United States	58%	65%	56%	68%
Puerto Rico	13%	*	13%	*
Canada	*	10%	*	10%
All other countries	29%	25%	31%	22%

^__________

* Less than 10% of segment’s total revenues for the period.

Contract Balances

The opening and closing balances of the Company's contract assets and contract liabilities are as follows (in thousands):



	September 27, 2019		December 28, 2018
Contract assets included in prepaid expenses and other current assets	$	10,561	$	—
Contract liabilities included in accrued expenses and other current liabilities	2,079		2,264

During the three and nine months ended September 27, 2019, the Company recognized $0.4 million and $0.8 million, respectively, of revenue that was included in the contract liability balance as of December 28, 2018. During the three and nine months ended September 28, 2018, the Company recognized $0.2 million and $0.6 million, respectively, of revenue that was included in the contract liability balance as of December 29, 2017.

- 30 -

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q should be read in conjunction with the disclosures included in our Annual Report on Form 10-K for the fiscal year ended December 28, 2018. In addition, please read this section in conjunction with our Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements contained herein.

Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include statements relating to:


•	future sales, expenses, and profitability;


•	future development and expected growth of our business and industry;


•	our ability to execute our business model and our business strategy;


•	our ability to identify trends within our industries and to offer products and services that meet the changing needs of those markets;


•	our ability to remain in compliance with the financial covenants contained in the agreement governing our Senior Secured Credit Facilities; and


•	projected capital expenditures.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or “variations” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: our indebtedness, our inability to pay principal and interest on this outstanding indebtedness or to remain in compliance with financial and other covenants under our Senior Secured Credit Facilities, and the risk that this indebtedness limits our ability to invest in our business and overall financial flexibility; our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement cost savings and consolidation initiatives; our reliance on third-party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high-quality standards for our products; challenges to our intellectual property rights; product liability claims; product field actions or recalls; our inability to successfully consummate and integrate acquisitions and to realize synergies and to operate these acquired businesses in accordance with expectations; our unsuccessful expansion into new markets; our failure to develop new products; the timing, progress and ultimate success of pending regulatory actions and approvals; our inability to obtain licenses to key technology; regulatory changes, including health care reform, or consolidation in the healthcare industry; global economic factors, including currency exchange rates and interest rates; the resolution of various legal actions brought against the Company; ongoing impacts resulting from the U.S. Tax Cuts and Jobs Act (the “Tax Reform Act”), including the Global Intangible Low-Taxed Income (“GILTI”) tax; and other risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in other periodic filings with the Securities and Exchange Commission. Except as required by applicable law, the Company assumes no obligation to update forward-looking statements in this report whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

In this Form 10-Q, references to “Integer,” “we,” “us,” “our” and the “Company” mean Integer Holdings Corporation and its subsidiaries, unless the context indicates otherwise.

- 31 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

Our Business

Integer Holdings Corporation is one of the largest medical device outsource (“MDO”) manufacturers in the world serving the cardiac, neuromodulation, vascular, orthopedics, advanced surgical and portable medical markets. We also develop batteries for high-end niche applications in the non-medical energy, military, and environmental markets. Our vision is to enhance the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

We organize our business into two reportable segments, Medical and Non-Medical, and derive our revenues from four principal product lines. The Medical segment includes the Advanced Surgical, Orthopedics & Portable Medical, Cardio & Vascular and Cardiac & Neuromodulation product lines and the Non-Medical segment is comprised of the Electrochem product line.

Historically, we have utilized a 52/53-week fiscal year ending on the Friday nearest December 31. On October 9, 2019, Integer’s Board of Directors approved a change in our fiscal year from a year ending on the Friday nearest December 31 to a year ending on December 31 each year. Upon receipt of the customary approval of the lenders under our Senior Secured Credit Facilities, our current fiscal year will end on December 31, 2019, instead of January 3, 2020, with subsequent fiscal years beginning on January 1 and ending on December 31 of each year. The change in fiscal year was implemented so that, on a going forward basis, each of our fiscal years (except for leap years) has 365 days, which will allow for consistent comparison between fiscal years. Our first three fiscal quarters in each fiscal year will continue to end on the Friday nearest March 31, June 30 and September 30, respectively. Fiscal year 2018 ended on December 28, 2018 and was a fifty-two week period.

The third quarter of 2019 and 2018 each contained 13 weeks and ended on September 27 and September 28, respectively, and were not impacted by the change in fiscal year.

Discontinued Operations and Divestiture

On July 2, 2018, we completed the sale of the Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) for net cash proceeds of approximately $581 million, resulting in the recognition of a pre-tax gain of approximately $195 million during the year ended December 28, 2018. In connection with the sale, the parties executed a transition services agreement whereby we provided certain corporate services (including accounting, payroll, and information technology services) to Viant to facilitate an orderly transfer of business operations. Viant paid us for these services as specified in the transition services agreement, which were complete as of June 28, 2019. In addition, the parties executed long-term supply agreements under which the parties have agreed to supply the other with certain products at prices specified in the agreements for a term of three years.

On June 14, 2019, Viant paid us $4.8 million for the final net working capital adjustment, which was recognized as gain on sale from discontinued operations, net of taxes, during the quarter ended June 28, 2019.

The results of operations of the AS&O Product Line have been classified as discontinued operations for all periods presented. Prior period amounts have been reclassified to conform to the continuing operations reporting presentation. All results and information presented exclude the AS&O Product Line unless otherwise noted.

Refer to Note 2 “Discontinued Operations, Divestitures and Acquisitions” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about the divestiture of the AS&O Product Line.

Recent Acquisitions

In October 2019, we purchased certain assets of US BioDesign, LLC, a developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The acquisition adds a differentiated capability related to the development and manufacture of complex braided and formed biomedical structures to our broad portfolio, that we believe further positions us as a partner of choice for innovative medical technologies.

Strategic Overview

We continue to take steps to better align our resources in order to invest to grow, protect, preserve and to enhance the profitability of our portfolio of products. In addition to our portfolio strategy, we have launched the execution of six key operational strategic imperatives designed to drive excellence in everything we do:


•	Sales Force Excellence: We are changing the organization structure to match product line growth strategies and customer needs. This change is about getting more out of the capabilities we already have, and will increase individual accountability and clarity of ownership.


•	Market Focused Innovation: We are ensuring we get the most return on our research and development investments. Integer is currently focusing on getting a clearer picture of how we spend our money and ensuring we are spending it in the right places so we can increase investments to drive future growth.

- 32 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

•

Manufacturing Excellence: The goal is to deliver world-class operational performance in the areas of safety, quality, delivery and overall efficiency. We want to transition our manufacturing into a competitive advantage through a single, enterprise-wide manufacturing structure known as the Integer Production System. This system will provide standardized systems and processes by leveraging best practices and applying them across all of our global sites.


•	Business Process Excellence: Integer is taking a systematic approach to driving excellence in everything we do by standardizing, optimizing and ultimately sustaining all of our processes.

•

Performance Excellence: We are raising the bar on associate performance to maximize our impact. This includes aligning key roles with critical capabilities, positioning the best talent against the biggest work, and putting tools and processes in place to provide higher financial rewards for top performers, so our top performers can see increased results in pay for increased results in their performance.


•	Leadership Capability: We have a robust plan to make leadership a competitive advantage for Integer, and since the success rate is higher with internal hires, we are focusing on finding and developing leaders from within the Company to build critical capabilities for future success.

We believe Integer is well-positioned within the medical technology and MDO manufacturing market and that there is a robust pipeline of opportunities to pursue. We have expanded our medical device capabilities and are excited about opportunities to partner with customers to drive innovation. We believe we have the scale and global presence, supported by world-class manufacturing and quality capabilities, to capture these opportunities. We are confident in our capabilities as one of the largest MDO manufacturers, with a long history of successfully integrating companies, driving down costs and growing revenues over the long-term. Ultimately, our strategic vision is to drive shareholder value by enhancing the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

Revised 2019 Outlook^(a)

(dollars in millions, except per share amounts)



	GAAP		Non-GAAP^(b)
Continuing Operations:	As Reported	Growth	Adjusted	Growth
Sales	$1,265 to $1,280	4% to 5%	$1,265 to $1,280	4% to 6%
Income	$106 to $110	125% to 134%	$150 to $154	21% to 23%
EBITDA	N/A	N/A	$282 to $286	9% to 10%
Earnings per Diluted Share	$3.22 to $3.32	123% to 130%	$4.55 to $4.65	20% to 22%

(a)

Except as described below, further reconciliations by line item to the closest corresponding financial measure prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for Adjusted Sales, Adjusted Income, earnings before interest, taxes, depreciation, and amortization (“EBITDA”), and Adjusted EBITDA and Adjusted Earnings per diluted share (“EPS”), all from continuing operations, included in our “2019 Outlook” above, are not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and visibility of the charges excluded from these non-GAAP financial measures.

(b)

Adjusted income and diluted EPS, both from continuing operations, for 2019 are expected to consist of GAAP income from continuing operations and diluted EPS from continuing operations, excluding items such as intangible amortization, certain legal expenses, reorganization and realignment costs, asset dispositions, severance, gains and losses on equity investments and loss and loss on extinguishment of debt totaling approximately $56 million, pre-tax. The after-tax impact of these items is estimated to be approximately $44 million, or approximately $1.33 per diluted share.

Adjusted EBITDA from continuing operations is expected to consist of Adjusted income from continuing operations, excluding items such as depreciation, interest, stock-based compensation and taxes, which are expected to be approximately $132 million.

- 33 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

Financial Overview of Continuing Operations

Income from continuing operations for the third quarter of 2019 was $30.6 million, or $0.92 per diluted share, compared to a loss from continuing operations of $8.3 million, or $0.26 per diluted share, for the third quarter of 2018. Income from continuing operations for the first nine months of 2019 was $80.2 million, or $2.43 per diluted share per diluted share, compared to income from continuing operations of $27.8 million, or $0.86 per diluted share, for the first nine months of 2018. These year over year variances are primarily the result of the following:

•

Sales from continuing operations for the third quarter of 2019 decreased $1.5 million and increased $20.5 million for the first nine months of 2019 when compared to the same periods in 2018. The increase for the first nine months of 2019 was due to growth in Cardio & Vascular, Cardiac & Neuromodulation and Electrochem sales, partially offset by lower Advanced Surgical, Orthopedic & Portable Medical sales in comparison to the first nine months of 2018. During the third quarter and first nine months of 2019, price reductions given to our larger OEM customers in return for long-term volume commitments lowered sales by $3.2 million and $9.6 million, respectively, in comparison to the same periods in 2018. In comparison to the prior year periods, foreign currency exchange rates decreased sales from continuing operations by approximately $0.6 million and $2.2 million for the third quarter and first nine months of 2019, respectively.

•

Gross profit from continuing operations for the third quarter of 2019 increased $1.5 million, compared to the same period in 2018, primarily due to a $3.0 million decrease in cost of sales, partially offset by a decrease in sales and price reductions given to our customers. Gross profit from continuing operations for the first nine months of 2019 increased $4.8 million, compared to the same period in 2018, primarily due to the increase in sales from continuing operations and benefits of production efficiencies achieved, partially offset by price reductions given to our customers and inflation.


•	Operating expenses for the third quarter and first nine months of 2019 were lower by $3.6 million and $14.4 million, respectively, compared to the same periods in 2018, due to decreases in all categories of operating expenses.

•

Interest expense for the third quarter and first nine months of 2019 decreased by $42.2 million and $45.6 million, respectively, compared to the same periods in 2018, primarily due to lower outstanding debt balances due to the repayment of debt over the last year and extinguishment of debt charges included in the 2018 periods related to the repayment of indebtedness in connection with the divestiture of the AS&O Product Line. Debt extinguishment expenses included in interest expense for the third quarter and first nine months of 2019 were lower by $40.4 million and $40.9 million, respectively, compared to the same periods in 2018.


•	During the third quarter and first nine months of 2019, we recognized a net gain on equity investments of $1.0 million and a net loss of $0.7 million, respectively, and net gains for the third quarter and first nine months of 2018 of $0.3 million and $5.5 million, respectively. Gains and losses on equity investments are generally unpredictable in nature.


•	Other income, net for the third quarter and first nine months of 2019 was $0.4 million and $0.9 million, respectively, compared to other loss of $1.7 million and $0.3 million during the same periods in 2018, primarily due to foreign currency gains in the 2019 periods compared to foreign currency losses for the same periods in 2018.

•

We recorded an income tax provision of $4.9 million for the third quarter of 2019, compared to a benefit of $6.2 million for the third quarter of 2018. The income tax provision for the first nine months of 2019 and 2018 was $15.3 million and $8.0 million, respectively. Refer to Note 9 “Income Taxes” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report and the “Provision for Income Taxes” section of this Item for additional information.

Our CEO’s View

We delivered strong income growth in the third quarter, on flat sales. We continue to execute on our operational strategy and have increased our full year profit outlook. In the fourth quarter of 2019, we executed a bolt-on acquisition to add complex braiding for high-growth C&V markets. Strong cash flow generation enabled continued reductions to our debt leverage ratio.

- 34 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

Our Financial Results of Continuing Operations

The following tables present selected financial information from continuing operations derived from our Condensed Consolidated Financial Statements, contained in Item 1 of this report, for the periods presented (dollars in thousands, except per share). All financial information presented is from continuing operations unless otherwise specified.



	Three Months Ended
	September 27,			September 28,			Change
	2019			2018			$			%
Medical Sales:
Cardio & Vascular	$	148,581		$	150,230		$	(1,649	)	(1.1	)%
Cardiac & Neuromodulation	106,533			109,620			(3,087		)	(2.8	)%
Advanced Surgical, Orthopedics & Portable Medical	34,310			32,789			1,521			4.6	%
Total Medical Sales	289,424			292,639			(3,215		)	(1.1	)%
Non-Medical	14,163			12,449			1,714			13.8	%
Total Sales	303,587			305,088			(1,501		)	(0.5	)%
Cost of sales	210,201			213,165			(2,964		)	(1.4	)%
Gross profit	93,386			91,923			1,463			1.6	%
Gross profit as a % of sales	30.8		%	30.1		%
Selling, general and administrative expenses (“SG&A”)	32,935			34,091			(1,156		)	(3.4	)%
SG&A as a % of sales	10.8		%	11.2		%
Research, development and engineering costs (“RD&E”)	11,729			12,234			(505		)	(4.1	)%
RD&E as a % of sales	3.9		%	4.0		%
Other operating expenses	2,241			4,139			(1,898		)	(45.9	)%
Operating income	46,481			41,459			5,022			12.1	%
Operating margin	15.3		%	13.6		%
Interest expense	12,337			54,526			(42,189		)	(77.4	)%
Gain on equity investments, net	(986		)	(291		)	(695		)	^NM
Other (income) loss, net	(369		)	1,684			(2,053		)	^NM
Income (loss) from continuing operations before taxes	35,499			(14,460		)	49,959			^NM
Provision for (benefit from) income taxes	4,913			(6,157		)	11,070			^NM
Effective tax rate	13.8		%	42.6		%
Income (loss) from continuing operations	$	30,586		$	(8,303	)	$	38,889		^NM
Income (loss) from continuing operations as a % of sales	10.1		%	(2.7		)%
Diluted earnings (loss) per share from continuing operations	$	0.92		$	(0.26	)	$	1.18		^NM

- 35 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS



	Nine Months Ended
	September 27,			September 28,			Change
	2019			2018			$			%
Medical Sales:
Cardio & Vascular	$	451,552		$	435,859		$	15,693		3.6	%
Cardiac & Neuromodulation	337,932			334,471			3,461			1.0	%
Advanced Surgical, Orthopedics & Portable Medical	98,544			101,481			(2,937		)	(2.9	)%
Total Medical Sales	888,028			871,811			16,217			1.9	%
Non-Medical	44,429			40,167			4,262			10.6	%
Total Sales	932,457			911,978			20,479			2.2	%
Cost of sales	653,477			637,758			15,719			2.5	%
Gross profit	278,980			274,220			4,760			1.7	%
Gross profit as a % of sales	29.9		%	30.1		%
SG&A	101,034			107,300			(6,266		)	(5.8	)%
SG&A as a % of sales	10.8		%	11.8		%
RD&E	34,720			38,445			(3,725		)	(9.7	)%
RD&E, Net as a % of sales	3.7		%	4.2		%
Other operating expenses	8,239			12,615			(4,376		)	(34.7	)%
Operating income	134,987			115,860			19,127			16.5	%
Operating margin	14.5		%	12.7		%
Interest expense	39,779			85,355			(45,576		)	(53.4	)%
(Gain) loss on equity investments, net	666			(5,545		)	6,211			^NM
Other (income) loss, net	(921		)	257			(1,178		)	^NM
Income from continuing operations before taxes	95,463			35,793			59,670			^NM
Provision for income taxes	15,289			7,956			7,333			92.2	%
Effective tax rate	16.0		%	22.2		%
Income from continuing operations	$	80,174		$	27,837		$	52,337		^NM
Income from continuing operations as a % of sales	8.6		%	3.1		%
Diluted earnings per share from continuing operations	$	2.43		$	0.86		$	1.57		^NM

^NM Calculated amount not meaningful

- 36 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

Product Line Sales from Continuing Operations

For the third quarter and first nine months of 2019, Cardio & Vascular sales decreased $1.6 million, or 1%, and increased $15.7 million or 4%, respectively, versus the comparable 2018 periods. The decrease in the third quarter of 2019 compared to the same quarter in 2018 was primarily due to an end of life electrophysiology program, which experienced the largest quarterly decline to date, partially offset by peripheral vascular and structural heart growth. The increase in the first nine months of 2019 was driven by customer share gains, new product launches, and the impact of a long-term agreement with a current customer related to their existing products. During the third quarter and first nine months of 2019, price reductions lowered Cardio & Vascular sales by $1.4 million and $4.9 million, respectively, in comparison to the 2018 periods. Foreign currency exchange rate fluctuations decreased Cardio & Vascular sales for the third quarter and first nine months of 2019 by $0.7 million and $1.6 million, respectively, in comparison to the 2018 periods primarily due to U.S. dollar fluctuations relative to the Euro.

For the third quarter and first nine months of 2019, Cardiac & Neuromodulation sales decreased $3.1 million, or 3%, and increased $3.5 million or 1%, respectively, versus the comparable 2018 periods. The decrease in the third quarter of 2019 compared to the same quarter in 2018 was primarily due to neuromodulation customer demand shift to the fourth quarter and flat cardiac rhythm management sales. The increase in the first nine months of 2019 in Cardiac & Neuromodulation sales was mainly due to the impact of the aforementioned long-term customer agreement. During the third quarter and first nine months of 2019, price reductions lowered Cardiac & Neuromodulation sales by $1.7 million and $5.0 million, respectively, in comparison to the 2018 periods. Foreign currency exchange rate fluctuations did not have a material impact on Cardiac & Neuromodulation sales during the third quarter and first nine months of 2019 in comparison to the same periods of 2018.

In addition to Portable Medical sales, Advanced Surgical, Orthopedic & Portable Medical includes sales to the acquirer of our AS&O Product Line, Viant, under the long-term supply agreements (“LSAs”) entered into as of the closing of the divestiture for the sale of products by the Company to Viant. For the third quarter and first nine months of 2019, Advanced Surgical, Orthopedic & Portable Medical sales increased $1.5 million, or 5%, and decreased $2.9 million or 3%, respectively, versus the comparable 2018 periods. The quarterly sales increase was driven by an increase in the advanced surgical base products and new product launches in Portable Medical, which was more than offset on a year-to-date basis by a decline in advanced surgical and orthopedic products. Price reductions lowered Advanced Surgical, Orthopedic & Portable Medical sales for the third quarter and first nine months of 2019 by $0.2 million, in comparison to the 2018 periods. Foreign currency exchange rate fluctuations did not have a material impact on Advanced Surgical, Orthopedic & Portable Medical sales during the third quarter and first nine months of 2019 in comparison to the same periods of 2018.

For the third quarter and first nine months of 2019, Non-Medical sales increased $1.7 million, or 14%, and $4.3 million or 11%, respectively, versus the comparable 2018 periods. The increases in Non-Medical sales were primarily due to energy market demand and favorable military order timing. Price and foreign currency exchange rate fluctuations did not have a material impact on Non-Medical sales during the third quarter and first nine months of 2019 in comparison to the same periods of 2018.

- 37 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

Gross Profit

Changes to gross profit as a percentage of sales (“Gross Margin”) from the prior year were due to the following:



	Change From Prior Year
	Three Months		Nine Months
Price^(a)	(1.1	)%	(1.0	)%
Mix^(b)	(0.1	)	0.1
Incentive compensation^(c)	0.1		(0.1	)
Production efficiencies and volume leverage^(d)	1.8		0.8
Total percentage point change to gross profit as a percentage of sales	0.7	%	(0.2	)%

^__________


^(a)	Our Gross Margin for the third quarter and first nine months of 2019 has been negatively impacted by price reductions given to our larger OEM customers in return for long-term volume commitments.


^(b)	Amounts represent the impact to our Gross Margin attributable to favorable (unfavorable) changes in the mix of product sales during the period.


^(c)	Amounts represent the impact to our Gross Margin attributable to our cash and stock incentive compensation programs, including performance-based compensation, which is accrued based upon actual results achieved.


^(d)	Represents various increases and decreases to our Gross Margin. Overall, our Gross Margin for the third quarter and first nine months of 2019 was positively impacted by production efficiencies, mainly due to our Manufacturing Excellence initiative, as well as lower amortization expense and, on a year-to-date basis, higher sales volume.

SG&A Expenses

Changes to SG&A expenses from the prior year were due to the following (in thousands):



	Change From Prior Year
	Three Months			Nine Months
Transition services agreement^(a)	$	1,834		$	(924	)
Professional fees^(b)	(1,267		)	(1,094		)
Compensation and benefit costs	(748		)	(1,472		)
Depreciation and amortization	(86		)	(740		)
Other general and administrative expenses	(889		)	(2,036		)
Net decrease in SG&A Expenses	$	(1,156	)	$	(6,266	)

^__________

^(a)

Represents the amount included in SG&A Expenses, which was charged to Viant for transition services provided beginning in the third quarter of 2018 through the second quarter of 2019. We executed a transition services agreement in conjunction with the sale of the AS&O Product Line, whereby we agreed to provide certain corporate services (including accounting, payroll, and information technology services) to Viant to facilitate an orderly transfer of business operations. This provision of services under the agreement was completed during the second quarter of 2019.

^(b)

Professional fees decreased during the third quarter and first nine months of 2019 compared to the prior year period, primarily due to lower legal costs, including legal expenses incurred related to our on-going patent infringement case. Refer to Note 10 “Commitments and Contingencies” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for information related to this patent infringement litigation.

RD&E

RD&E costs for the three and nine months ended September 27, 2019 was $11.7 million and $34.7 million, respectively, compared to $12.2 million and $38.4 million for the three and nine months ended September 28, 2018. RD&E costs are influenced by the number and timing of in-process projects and labor hours and other costs associated with these projects. Our research and development initiatives continue to emphasize new product development, product improvements, and the development of new technological platform innovations.

- 38 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

Other Operating Expenses

Refer to Note 8 “Other Operating Expenses” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further information related to these initiatives. Other Operating Expenses (“OOE”) is comprised of the following (in thousands):



	Three Months Ended				Nine Months Ended
	September 27, 2019		September 28, 2018		September 27, 2019		September 28, 2018
Strategic reorganization and alignment^(a)	$	962	$	2,643	$	4,352	$	8,424
Manufacturing alignment to support growth^(b)	515		877		1,661		2,493
Consolidation and optimization expenses^(c)	—		137		—		698
Asset dispositions, severance and other^(d)	764		482		2,226		1,000
Total other operating expenses	$	2,241	$	4,139	$	8,239	$	12,615

^__________

^(a)

As a result of the strategic review of our customers, competitors and markets, we began taking steps in the fourth quarter of 2017 to better align our resources in order to enhance the profitability of our portfolio of products. These initiatives include improving our business processes and redirecting investments away from projects where the market does not justify the investment, as well as aligning resources with market conditions and our future strategic direction. Expenses for the third quarter and first nine months of 2019 and 2018 primarily consist of severance costs and fees for professional services.


^(b)	In 2017, we initiated several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of our facilities.


^(c)	During 2018, we incurred costs primarily related to the closure of our Clarence, NY facility.


^(d)	Amounts include expenses related to other initiatives not described above, which relate primarily to integration and operational initiatives to reduce costs and improve operational efficiencies. Expenses for the third quarter and first nine months of 2019 and 2018 primarily include severance costs and fees for professional services.

We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. For 2019, Other Operating Expenses is expected to be approximately $10 million to $13 million.

- 39 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

Interest Expense

Interest Expense for the three and nine months ended September 27, 2019 was $12.3 million and $39.8 million, respectively, compared to $54.5 million and $85.4 million for the three and nine months ended September 28, 2018. We paid down $36.3 million of debt during the third quarter of 2019 and $102.1 million during the first nine months of 2019 on our Term Loan Facilities. The weighted average interest rates paid on outstanding borrowings for the three and nine months ended September 27, 2019 was 4.96% and 5.08%, respectively, compared to 4.95% and 4.97%, for the comparable periods in 2018. The weighted average interest rates paid in 2019 reflect increases in LIBOR during 2018, partially offset by reductions to the applicable interest rate margin of our Term Loan A. Cash interest expense decreased $1.7 million and $4.3 million for the three and nine months ended September 27, 2019, when compared to the same periods in 2018, primarily due to the decrease in outstanding borrowings.

Debt related charges included in interest expense (i.e. debt issuance costs and discount amortization) for the three and nine months ended September 27, 2019 were $1.6 million and $5.3 million, respectively, compared to $42.1 million and $46.5 million for the three and nine months ended September 28, 2018. The decrease in debt related charges during the three and nine months periods of 2019 compared to the same periods in 2018 is primarily attributable to lower accelerated write-offs (losses from extinguishment of debt) of deferred fees and original issue discount related to prepayments of portions of our Term Loan B facility and Senior Notes during the respective periods and a “make-whole” premium of $31.3 million paid as a result of redeeming our Senior Notes in July 2018. We recognized losses from extinguishment of debt during the three and nine months ended September 27, 2019 of $0.3 million and $1.3 million, respectively, compared to $40.7 million and $42.1 million for the three and nine months ended September 28, 2018. See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our debt.

As of September 27, 2019, approximately 20% of our principal amount of debt outstanding was subject to variable rates, in comparison to approximately 79% as of December 28, 2018. During the second and third quarters of 2019, we entered into interest rate swap agreements that we expect will further reduce our exposure to fluctuations in the LIBOR rate. These swap agreements convert $475 million of our outstanding debt to fixed rate indebtedness for the next six to nine months, as well as extended our $200 million interest rate swap for an additional three years.

(Gain) Loss on Equity Investments, Net

During the three and nine months ended September 27, 2019, we recognized net gains of $1.0 million and net losses of $0.7 million, respectively, compared to net gains of $0.3 million and $5.5 million during the three and nine months ended September 28, 2018, respectively, on our equity investments. Gains and losses on equity investments are generally unpredictable in nature. During the second quarter of 2019, we recognized an impairment charge of $1.6 million related to an investment in one of our non-marketable equity securities. The residual amounts for 2019 and 2018 relate to our share of equity method investee gains/losses, including unrealized appreciation of the underlying interests of the investee. As of September 27, 2019 and December 28, 2018, we held $22.1 million and $22.8 million, respectively, of equity investments. See Note 14 “Financial Instruments and Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further details regarding these investments.

Other (Income) Loss, Net

Other (Income) Loss, Net for the three and nine months ended September 27, 2019 was income of $0.4 million and $0.9 million, respectively, compared to losses of $1.7 million and $0.3 million for the three and nine months ended September 28, 2018, respectively. Other (Income) Loss, Net is primarily comprised of income (loss) from the impact of foreign currency exchange rates on transactions denominated in foreign currencies. Our foreign currency transaction gains/losses are based on fluctuations of the U.S. dollar relative to the Euro, Mexican peso, Uruguayan pesos or Malaysian ringgits.

The impact of foreign currency exchange rates on transactions denominated in foreign currencies included in Other (Income) Loss, Net for the three and nine months ended September 27, 2019 were gains of $0.3 million and $0.4 million, respectively, compared to losses of $1.7 million and $0.8 million for the three and nine months ended September 28, 2018, respectively. We continually monitor our foreign currency exposures and seek to take steps to mitigate these risks. However, fluctuations in foreign currency exchange rates could have a significant impact, positive or negative, on our financial results in the future.

- 40 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

Provision for Income Taxes

We recognized income tax expense of $4.9 million (effective tax rate of 13.8%) for the third quarter of 2019 on $35.5 million of pre-tax income from continuing operations compared to income tax benefit of $6.2 million (effective tax rate of 42.6%) on $14.5 million of pre-tax loss from continuing operations for the same period of 2018. The income tax expense for the first nine months of 2019 was $15.3 million (effective tax rate of 16.0%) on income from continuing operations before taxes of $95.5 million compared to $8.0 million (effective tax rate of 22.2%) on $35.8 million of income from continuing operations before taxes for the same period of 2018.

Our effective tax rate for the third quarter and first nine months of 2019 differs from the third quarter and first nine months of 2018 due principally to the impact of the Global Intangible Low-Taxed Income (GILTI) tax, as well as the impact of our earnings realized in foreign jurisdictions with statutory rates that are different than the federal statutory rate. The GILTI provisions require the inclusion of our foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in our U.S. income tax return. There is a statutory deduction of 50% of the GILTI inclusion, however the deduction is subject to limitations based on U.S. taxable income. As of the third quarter of 2018, we had net operating losses to offset substantially all of our forecasted U.S. taxable income and as such, were temporarily subject to the deduction limitation, which correspondingly imposes an incremental impact on U.S. income tax. We are not forecasting a limitation of the GILTI deduction in 2019.

We expect continued volatility in our effective tax rate due to several factors including: changes in the mix of pre-tax income from continuing operations and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. We currently have various tax planning initiatives in place and continuously evaluate planning strategies aimed at reducing our effective tax rate over the long term. This includes strategies to realize deferred tax assets that would otherwise expire unutilized.

Our effective tax rate for 2019 differs from the U.S. federal statutory tax rate of 21% due principally to the net impact of the GILTI tax, the Company’s earnings outside the U.S., which are generally taxed at rates that differ from the U.S federal rate, and the availability of tax credits.

Our earnings outside the U.S. are generally taxed at blended rates that are marginally lower than the U.S. federal rate. The GILTI provisions require us to include foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in our U.S. income tax return. The foreign jurisdictions in which we operate and where our foreign earnings are primarily derived, include Switzerland, Mexico, Uruguay, Malaysia and Ireland. While we are not currently aware of any material trends in these jurisdictions that are likely to impact our current or future tax expense, our future effective tax rates could be adversely affected by earnings being lower than anticipated in countries where we have lower effective tax rates and higher than anticipated in countries where we have higher effective tax rates, or by changes in tax laws or regulations. We regularly assess any significant exposure associated with increases in tax rates in international jurisdictions and adjustments are made as events occur that warrant adjustment to our tax provisions.

- 41 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

Liquidity and Capital Resources



(dollars in thousands)	September 27, 2019		December 28, 2018
Cash and cash equivalents	$	14,719	$	25,569
Working capital	264,133		251,680
Current ratio	2.40		2.53

Cash and cash equivalents at September 27, 2019 decreased by $10.9 million from December 28, 2018 as excess cash on hand was used to pay down our debt. Working capital increased by $12.5 million from December 28, 2018, primarily due to an increase in accounts receivable, inventories and prepaid and other current assets, partially offset by the reduced cash balance and increase in accounts payable.

At September 27, 2019, $5.4 million of our cash and cash equivalents were held by foreign subsidiaries. We intend to limit our distributions from foreign subsidiaries to previously taxed income or current period earnings. If distributions are made utilizing current period earnings, we will record foreign withholding taxes in the period of the distribution.

Summary of Cash Flow



	Nine Months Ended
(in thousands)	September 27, 2019			September 28, 2018
Cash provided by (used in):
Operating activities	$	111,977		$	120,736
Investing activities	(20,382		)	549,155
Financing activities	(102,432		)	(692,896		)
Effect of foreign currency exchange rates on cash and cash equivalents	(13		)	1,790
Net change in cash and cash equivalents	$	(10,850	)	$	(21,215	)

The cash flow information presented includes cash flows related to the discontinued operations.

Operating Activities – During the nine months ended September 27, 2019, we generated cash from operations of $112.0 million compared to $120.7 million for the nine months ended September 28, 2018. This decrease was primarily due to a $21.2 million decrease in cash flow provided by working capital, partially offset by a $12.5 million increase in cash net income (i.e. net income plus adjustments to reconcile net income to net cash provided by operating activities). The cash flow from working capital change during the period was primarily due to higher accounts receivable due to timing as well as the payment of customer rebates.

Investing Activities – The $569.5 million decrease in net cash used in investing activities was primarily attributable to the lower net cash proceeds from the sale of the AS&O Product Line, partially offset by lower purchases of property, plant, and equipment, due to the sale of the AS&O Product Line. Investing activities for the nine months ended September 27, 2019 included $4.8 million of cash proceeds from Viant (received during the second quarter of 2019) resulting from the net working capital adjustment for the sale of the AS&O Product Line, compared to net cash proceeds from the sale of approximately $582 million (received during the third quarter of 2018).

Our current expectation is that capital purchases for 2019 will be in the range of $50 million to $55 million. We anticipate that cash on hand, cash flows from operations and available borrowing capacity under our Revolving Credit Facility will be sufficient to fund these capital expenditures.

Financing Activities – Net cash used in financing activities for the nine months ended September 27, 2019, was $102.4 million compared to $692.9 million in the comparable 2018 period. Financing activities during the first nine months of 2019 included net payments of $102.1 million related to paying down our debt obligations compared to $670.1 million for the comparable 2018 period.

In connection with the completion of the sale of our AS&O Product Line, during the third quarter of 2018 we repaid $548 million of our debt, which included $360 million of our 9.125% Senior Notes, $114 million of our Term Loan B Facility and $74 million outstanding on our Revolving Credit Facility.

- 42 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

Capital Structure – As of September 27, 2019, our capital structure consists of $828 million of debt, net of deferred fees and discounts, outstanding under our Senior Secured Credit Facilities and 33 million shares of common stock outstanding. We have access to $193 million of borrowing capacity under our Revolving Credit Facility. We are also authorized to issue up to 100 million shares of common stock and 100 million shares of preferred stock. Our debt service obligations, comprised of principal and interest payments for the remainder of 2019, are estimated to be approximately $20 million.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and potential borrowings under our Revolving Credit Facility are sufficient to meet our working capital, debt service and capital expenditure requirements for the next twelve months. If our future financing needs increase, we may need to arrange additional debt or equity financing. We continually evaluate and consider various financing alternatives to enhance or supplement our existing financial resources, including our Senior Secured Credit Facilities. However, we cannot be assured that we will be able to enter into any such arrangements on acceptable terms or at all.

Credit Facilities - As of September 27, 2019, we had senior secured credit facilities (the “Senior Secured Credit Facilities”) that consist of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), which had available borrowing capacity of $193.2 million as of September 27, 2019, (ii) a $277 million term loan A facility (the “TLA Facility”), and (iii) an $563 million term loan B facility (the “TLB Facility”). The Revolving Credit Facility will mature on October 27, 2020, the TLA Facility will mature on October 27, 2021 and the TLB Facility will mature on October 27, 2022.

The Revolving Credit Facility and TLA Facility contain financial covenants requiring (A) a maximum total net leverage ratio of 4.75:1.0, subject to quarterly step downs of 25 basis points beginning in the fourth quarter of 2019 and ending in the second quarter of 2020, and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of 3.0:1.0. The TLB Facility does not contain any financial maintenance covenants. As of September 27, 2019, our total net leverage ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 2.7 to 1.0. For the twelve month period ended September 27, 2019, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 6.5 to 1.0.

Failure to comply with these financial covenants would result in an event of default as defined under the Revolving Credit Facility and TLA Facility unless waived by the lenders. An event of default may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us. As of September 27, 2019, we were in full compliance with the financial covenants described above. As of September 27, 2019, our adjusted EBITDA would have to decline by approximately $129 million, or approximately 42%, in order for us to not be in compliance with our financial covenants. The Revolving Credit Facility is supported by a consortium of fourteen lenders with no lender controlling more than 27% of the facility.

See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further information on the Company’s outstanding debt.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board, Securities and Exchange Commission, or other authoritative accounting bodies to determine the potential impact they may have on our Condensed Consolidated Financial Statements. See Note 1 “Basis of Presentation” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.

Contractual Obligations

There have been no significant changes to our contractual obligations during the quarter ended September 27, 2019 as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 28, 2018.

- 43 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

Critical Accounting Policies and Estimates

The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.

There have been no significant changes to the critical accounting policies and estimates as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 28, 2018.

Use of Non-GAAP Financial Information

We prepare our condensed consolidated financial statements in accordance with GAAP. Additionally, we report and discuss in this management's discussion and analysis, our earnings releases and investor presentations adjusted pre-tax income, adjusted income, adjusted diluted EPS, EBITDA and adjusted EBITDA, all from continuing operations.

Adjusted pre-tax income, adjusted income and adjusted diluted EPS from continuing operations consist of GAAP amounts adjusted for the following to the extent occurring during the period: (i) acquisition and integration related charges and expenses, (ii) amortization of intangible assets, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain litigation expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) gain/loss on equity investments, (ix) extinguishment of debt charges, (x) the net impact of long-term supply agreements (“LSAs”) entered into as of the closing of the divestiture of the AS&O Product Line, (xi) the income tax (benefit) related to these adjustments (not for adjusted pre-tax income) and (xii) certain tax items that are outside the normal provision for the period (not for adjusted pre-tax income). Adjusted diluted EPS is calculated by dividing adjusted income from continuing operations by diluted weighted average shares outstanding.

EBITDA from continuing operations is calculated by adding back interest expense, GAAP provision (benefit) for income taxes, depreciation and amortization expense, to income from continuing operations, which is the most directly comparable GAAP measure. Adjusted EBITDA from continuing operations consists of EBITDA from continuing operations plus GAAP stock-based compensation and the same adjustments as listed above except for items (ii), (ix), (xi) and (xii).

We believe that the presentation of adjusted income, adjusted diluted EPS, EBITDA, and adjusted EBITDA, all from continuing operations, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations, including compliance with our bank covenant calculations.

- 44 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

Income from Continuing Operations and Diluted EPS Reconciliations

A reconciliation of GAAP income (loss) from continuing operations and diluted EPS from continuing operations to adjusted amounts is as follows (in thousands, except per share amounts):



	Three Months Ended
	September 27, 2019									September 28, 2018
	Pre-Tax			Net of Tax			Per Diluted Share			Pre-Tax			Net of Tax			Per Diluted Share
Income (loss) from continuing operations (GAAP)	$	35,499		$	30,586		$	0.92		$	(14,460	)	$	(8,303	)	$	(0.26	)
Adjustments:
Amortization of intangibles^(a)	9,782			7,750			0.23			9,896			7,830			0.24
Certain legal expenses (SG&A)^(a)(b)	99			78			—			749			591			0.02
Strategic reorganization and alignment (OOE)^(a)(c)	962			740			0.02			2,643			2,085			0.06
Manufacturing alignment to support growth (OOE)^(a)(d)	515			366			0.01			877			657			0.02
Consolidation and optimization expenses (OOE)^(a)(e)	—			—			—			137			108			—
Asset dispositions, severance and other (OOE)^(a)(f)	764			604			0.02			482			412			0.01
Gain on equity investments, net^(a)	(986		)	(779		)	(0.02		)	(291		)	(230		)	(0.01		)
Loss on extinguishment of debt^(a)(g)	291			230			0.01			40,654			32,117			0.98
Tax adjustments^(h)	—			—			—			—			(417		)	(0.01		)
Adjusted income from continuing operations (Non-GAAP)	$	46,926		$	39,575		$	1.20		$	40,687		$	34,850		$	1.06

Diluted weighted average shares for adjusted EPS^(j)				33,068									32,899

	Nine Months Ended
	September 27, 2019									September 28, 2018
	Pre-Tax			Net of Tax			Per Diluted Share			Pre-Tax			Net of Tax			Per Diluted Share
Income from continuing operations (GAAP)	$	95,463		$	80,174		$	2.43		$	35,793		$	27,837		$	0.86
Adjustments:
Amortization of intangibles^(a)	29,467			23,324			0.71			31,068			24,523			0.75
Certain legal expenses (SG&A)^(a)(b)	2,175			1,718			0.05			1,546			1,221			0.04
Strategic reorganization and alignment (OOE)^(a)(c)	4,352			3,377			0.10			8,424			6,662			0.20
Manufacturing alignment to support growth (OOE)^(a)(d)	1,661			1,173			0.04			2,493			1,841			0.06
Consolidation and optimization expenses (OOE)^(a)(e)	—			—			—			698			553			0.02
Asset dispositions, severance and other (OOE)^(a)(f)	2,226			1,756			0.05			1,000			776			0.02
(Gain) loss equity investments, net^(a)	666			526			0.02			(5,545		)	(4,381		)	(0.13		)
Loss on extinguishment of debt^(a)(g)	1,265			999			0.03			42,128			33,281			1.02
LSA adjustments^(a)(i)	—			—			—			(6,119		)	(4,834		)	(0.15		)
Tax adjustments^(h)	—			—			—			—			2,534			0.08
Adjusted income from continuing operations (Non-GAAP)	$	137,275		$	113,047		$	3.42		$	111,486		$	90,013		$	2.75

Diluted weighted average shares for adjusted EPS^(j)				33,019									32,681

^__________

- 45 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

^(a)

The difference between pre-tax and net of tax amounts is the estimated tax impact related to the respective adjustment. Net of tax amounts are computed using a 21% U.S. tax rate, and the statutory tax rates in Mexico, Netherlands, Uruguay, Ireland and Switzerland, as adjusted for the existence of net operating losses (“NOLs”). Amortization of intangibles and other operating expense for 2018 were adjusted to reflect the estimated impact relating to our disallowed deduction of the GILTI tax, as described in footnote (h) below. Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.

^(b)

In 2013, we filed suit against AVX Corporation alleging it was infringing our intellectual property. Given the complexity and significant costs incurred pursuing this litigation, we are excluding these litigation expenses from adjusted amounts. This matter proceeded to trial during the first quarter of 2016 and again in the third quarter of 2017 that resulted in a jury awarding damages in the amount of $37.5 million. In March 2018, the court vacated that damage award and ordered a new trial on damages. In the January 2019 retrial on damages, the jury awarded damages in the amount of $22.2 million. To date, no gains have been recognized in connection with this litigation. The third quarter and nine months ended September 27, 2019 also includes costs associated with a legal matter to which we are a non-party witness.

^(c)

Amounts include expenses related to implementing our strategy that is designed to better align our resources in order to invest to grow, protect, preserve and to enhance the profitability of our portfolio of products, including focusing our investment in RD&E and manufacturing, improving our business processes and redirecting investments away from projects where the market does not justify the investment. During 2019 and 2018, we incurred charges related to this strategy, which primarily consisted of severance costs and fees for professional services.


^(d)	Includes expenses related to several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of our facilities.


^(e)	During 2018, we incurred costs primarily related to the closure of our Clarence, NY facility.


^(f)	Amounts include expenses related to other initiatives not described above, which relate primarily to integration and operational initiatives to reduce costs and improve operational efficiencies.


^(g)	Represents debt extinguishment charges in connection with pre-payments made on our Term Loan B Facility, which are included in interest expense.

^(h)

The tax adjustment for 2018 represents the estimated impact relating to our disallowed deduction of the GILTI tax, as mandated by the Tax Reform Act. This disallowed deduction of the GILTI tax (approximately 50% of the total GILTI tax) is due to the Company making use of its U.S. NOLs during 2018. This adjustment makes our adjusted diluted EPS from continuing operations more comparable with other global companies that are not subject to this disallowed GILTI tax deduction and more comparable to the Company’s results following the full utilization of its U.S. NOLs.


⁽ⁱ⁾	Reflects the net impact of the LSAs entered into as of the closing of the divestiture of the AS&O Product Line. These LSAs govern the sale of products supplied by Viant to the Company for further resale to customers and by the Company to Viant for further resale to customers.


^(j)	The diluted weighted average shares for adjusted EPS for the three and nine months ended September 28, 2018 includes potentially dilutive shares not included in the computation of diluted weighted average common shares for GAAP diluted EPS purposes because their effect would have been anti-dilutive.

- 46 -

INTEGER HOLDINGS CORPORATION

MANAGEMENT'S DISCUSSION AND ANALYSIS

EBITDA and Adjusted EBITDA Reconciliation

A reconciliation of GAAP income (loss) from continuing operations to EBITDA from continuing operations and adjusted EBITDA from continuing operations is as follows (dollars in thousands):



	Three Months Ended						Nine Months Ended
	September 27, 2019			September 28, 2018			September 27, 2019		September 28, 2018
Income (loss) from continuing operations (GAAP)	$	30,586		$	(8,303	)	$	80,174	$	27,837

Interest expense	12,337			54,526			39,779		85,355
Provision for (benefit from) income taxes	4,913			(6,157		)	15,289		7,956
Depreciation	9,080			9,960			27,930		29,929
Amortization	9,782			9,896			29,467		31,068
EBITDA from continuing operations (Non-GAAP)	66,698			59,922			192,639		182,145
Certain legal expenses	99			749			2,175		1,546
Stock-based compensation (excluding OOE)	1,392			2,087			6,778		7,265
Strategic reorganization and alignment	962			2,643			4,352		8,424
Manufacturing alignment to support growth	515			877			1,661		2,493
Consolidation and optimization expenses	—			137			—		698
Asset dispositions, severance and other	764			482			2,226		1,000
(Gain) loss on equity investments, net	(986		)	(291		)	666		(5,545		)
LSA adjustments	—			—			$	—	$	(6,119	)
Adjusted EBITDA from continuing operations (Non-GAAP)	$	69,444		$	66,606		$	210,497	$	191,907

- 47 -

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Refer to information appearing under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q. Furthermore, a discussion of market risk exposures is included in Part II, Item 7A, Quantitative and Qualitative Disclosure about Market Risk, of the Company’s Annual Report on Form 10-K for the year ended December 28, 2018. There have been no material changes in reported market risk since the inclusion of this discussion in the Company’s Annual Report on Form 10-K referenced above.

ITEM 4. CONTROLS AND PROCEDURES


a.	Evaluation of Disclosure Controls and Procedures

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the Securities and Exchange Commission as of September 27, 2019. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based on their evaluation, as of September 27, 2019, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.


b.	Changes in Internal Control Over Financial Reporting

During the Company’s most recent fiscal quarter, there have been no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

- 48 -

PART II—OTHER INFORMATION


ITEM 1.	LEGAL PROCEEDINGS

There were no new material legal proceedings that are required to be reported in the quarter ended September 27, 2019, and no material developments during the quarter in the Company’s legal proceedings as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 28, 2018, except that with respect to the AVX litigation, (i) on July 31, 2019, the U.S. District Court for the District of Delaware entered an order denying AVX’s post-trial motion to overturn the jury verdict in favor of the Company, (ii) on August 23, 2019, AVX filed its notice of appeal with the United States Court of Appeals for the Federal Circuit, and (iii) on September 5, 2019, the Company filed its notice of cross-appeal with the United States Court of Appeals for the Federal Circuit.


ITEM 1A.	RISK FACTORS

There have been no material changes to the Company’s risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 28, 2018.


ITEM 6.	EXHIBITS



Exhibit Number		Description

31.1*		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act.

31.2*		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act.

32.1**		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*		XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH*		XBRL Extension Schema Document

101.CAL*		XBRL Extension Calculation Linkbase Document

101.LAB*		XBRL Extension Label Linkbase Document

101.PRE*		XBRL Extension Presentation Linkbase Document

101.DEF*		XBRL Extension Definition Linkbase Document

104		Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).



*	Filed herewith.
**	Furnished herewith.
#	Indicates exhibits that are management contracts or compensation plans or arrangements.

- 49 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



Dated:	October 31, 2019	INTEGER HOLDINGS CORPORATION

		By:	/s/ Joseph W. Dziedzic
			Joseph W. Dziedzic
			President and Chief Executive Officer
			(Principal Executive Officer)

		By:	/s/ Jason K. Garland
			Jason K. Garland
			Executive Vice President and Chief Financial Officer
			(Principal Financial Officer)

		By:	/s/ Tom P. Thomas
			Tom P. Thomas
			Vice President, Corporate Controller
			(Principal Accounting Officer)

- 50 -

Integer Holdings - 10-Q quarterly report FY2019 Q3

What is the market capitalization of a company?

DISCLAIMER

Contact

Links